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Immunoassays by Flow Injection Analysis — Arwel Hughes
Abstract
A home—built flow injection analysis (FIA) system 
was fully automated using an Apple lie microcomputer, 
and subsequently used as a versatile system for the 
study of immunoassay procedures. The performance of the 
automated system was monitored by using the 
turbidimetric detection of barium sulphate as a model.
A model immunoassay between concanavalin A 
(antibody) and yeast mannan (antigen) was investigated 
using the computer controlled FIA system. The automated 
injection procedure gave acceptable precision XRSD<6 
for a turbidimetric method and the stop—flow merging 
zones technique used gave an acceptable sample 
throughput (40 samples hour— M  with minimal consumption 
of both sample and reagent (30 ul per analysis).
An immunological reaction between human serum 
immunoglobulin G (IgG) and goat anti—human IgG was 
investigated using a similar system to the above. 
Turbidimetric detection at 340 , nm was used to monitor 
the rate of reaction. A sampling rate of 40 samples 
hour-1 and a precision of 2.0—6.8 y£RSD was obtained for 
a range of human standards. Serum samples and a human 
reference serum were analysed and their IgG 
concentrations interpolated from the calibration data. 
Satisfactory correlation (r=0.9881) was observed with 
the existing technique of radial immunodiffusion, as 
used at Doncaster Royal Infirmary, over the range
0—2844 mg dl— 1 IgG.
Efforts to increase the sensitivity of the method 
for IgG determinations were based on enzyme immunoassay 
procedures, using urease as the enzyme label on the 
antibody. A homogeneous EMIT type assay for IgG was 
studied using the computer controlled FIA system. 
However the expected increase in sensitivity was not 
achieved. A pseudo heterogeneous ELISA type assay for 
IgG was also studied, a method which allowed for 
further reduction in consumption of expensive reagents 
by immobilising the enzyme conjugate on controlled pore 
glass or polystyrene. The results presented demonstrate 
that both EMIT and ELISA type assays are possible using 
FIA, however on this occasion problems of sensitivity 
did not allow for determinations using real samples.
The determination of ABO blood grouping is the first 
qualitative application of FIA that has been reported. 
Results for 20 human red cell samples using the 
automated FIA system correlated well with results 
obtained by an automated agglutination technique used 
at the Blood Transfusion Service, Sheffield.
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1INTRODUCTION
One of the major developments in analytical chemistry 
has been the increasing demand for the determination of 
individual components in biological fluids<x>. Such analyses 
present the twin problems of specificity and sensitivity. 
The complex composition of the samples containing as they do 
many distinct, but similar species has resulted in the 
development of immunoassays which combine specificity with 
low detection limits for the analyte of interest. 
Immunoprecipitin assays have been historically used for the 
analysis of serum proteins while labelled immunoassay 
procedures have been used extensively for the analysis of 
drugs of abuse and hormones. The very high sensitivities 
required of the analytical procedures result from the small 
volume of samples available, especially in paediatrics, 
and/or the low concentration of the analyte in the sample.
Furthermore there is the need for rapid, cheap and 
easily automated assays. The results presented in this 
thesis will show that flow injection analysis <FIA) 
techniques offer a range of features such as flexibility of 
modes of operation, small sample/reagent consumption and 
speed that are ideal for many aspects of this work. They 
will also demonstrate in what directions further research is 
required in order to extend its application still further.
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1.1 Immunoassays
A definition of immunology is the science of the 
vertebrate animal's recognition of, specific response to, 
and subsequent memory of, an antigen, and the reaction 
between the product of that response (antibody) and the 
antigen which invoked its production, to make the animal 
exempt from i n f e c t i o n . Thus, the immunological defence 
mechanism of man and other animals involves the production 
of vital antibodies. These antibodies are synthesised in the 
body to combat circulating toxins or macromolecules which 
are foreign to that body. The substances which invoke the 
production of antibodies are termed antigens, and are 
generally naturally occuring macromolecules (proteins, 
polysaccharides, nucleic acids) or micro—organisms
(bacteria, viruses). Since the number of possible antigens 
is vast, it is therefore evident that animals must be
capable of synthesising many antibodies. Thus, the 
specificity of immune reactions (antigen—antibody reactions) 
derives from the fact that a particular antibody molecule is 
highly specific to the foreign body that evoked its 
formation. The above mentioned reaction is known as the
immune response, which is the basis for the field of 
immunology.
A basic representation of the immune response is 
depicted in Figure 1.1. Injection of a pure antigen,
typically a human plasma protein, into the test animal
causes the animal to synthesise antibodies specific to the
2
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injected antigen. Since antigen—antibody reactions are 
specific, it is generally unnecessary to isolate antibodies 
■from the blood serum o-f the test animal in which they are 
produced. The whole serum (antiserum) is used in many 
assays. However, the use of purified antibodies, which are 
advantageous in several immunoassays, is becoming more 
popular, due to the exclusion of similar species from the 
antiserum which may give rise to non-specific responses. 
These antibodies then combine non—covalent1y with the 
antigen:
i) 'in—vivo' — to abolish the harmful effects of the
antigen
ii) 'in—vitro' — forming complexes, the measurement of which
constitutes an immunoassay 
Thus, not only do antibodies fulfil many crucial functions 
in the immunological defence mechanism of man and other 
animals, but they are also of importance in another role, as 
a series of very specific analytical reagents. Immunoassays 
are now used routinely in many laboratories for the 
determination of both macromolecules and low molecular 
weight compounds (haptens).
Anti gen-antibody reactions produce different phenomena 
according to the nature of the antigen. Soluble 
macromolecular antigens may combine with antibodies to form 
precipitates as shown by Kraus in 1897 (Chapter 3) while 
cellular antigens may be agglutinated by the multivalent 
antibodies to form clumps of cells (Chapter 5). Early work
suggested that even though natural antigens were normally 
macromolecular, only relatively small regions of antigens, 
termed antigenic determinands, were actually involved in the 
chemical bonding to antibody. Landsteiner<3) extended this 
finding by demonstrating that small molecules, while not 
causing antibody production on their own, could be made to 
do so by coupling them to macromolecular carriers (proteins 
or synthetic polypeptides) before injecting them into the 
test animal. The resulting antibodies react with the small 
molecules alone as well as with the small molecule—carrier 
conjugate- Such small molecules are known as haptens e.g. 
azobenzoate and nitrophenol derivatives.
Thus, it is apparent that any micro-organism or 
molecule that is, or can be made to be, antigenic, may be 
analysed immunologically. Antibodies which are raised in 
test animals (as antisera) are the reagents used in
analytical assays and the assay usually involves the
detection and determination of antigen (hapten)—antibody 
complexes. It is important to realise however, that
molecules that are antibodies in one species (e.g. human
IgG) will be antigenic in another species (e.g. human IgG in 
goats), and thus may be determined immunologically.
Thus far, mention has been made of the combination of 
antigen and antibody. The combination does not involve the 
formation of a fixed chemical compound by forming covalent 
links, but involves weaker inter—molecular forces(4>. This 
results in an aggregation of antigen and antibody molecules
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in differing molecular proportions in varying circumstances, 
held by bands o-f various strengths- Four main types of 
linkages exist:
i) Coulombic forces- which arise from electrostatic 
attraction between oppositely charged groups in the 
antigen and in the amino—acid side chains of the 
antibody.
ii) Hydrogen bonds— weak bonds produced between hydrogen 
donating groups such as —OH, —NHZ , —COOH of 
amino-acid side chains and the amide type linkages 
of the peptide bond, —CO—NH— , of a polypeptide 
molecule.
iii) Hydrophobic forces— occur between non—polar groups 
which are able to approach so closely that they exclude 
water molecules.
iv) Van der Waal's forces— forces which depend upon the 
interactions between electron clouds surrounding 
approaching molecules.
The weak forces allow the antigen—antibody reaction to 
be reversible and the antigens and their corresponding 
antibodies maintain a state of dynamic equilibrium wherein 
random bonds are constantly forming and being broken < = **»> . 
At equlibrium the relative concentrations of reactants and 
products remain constant.
The whole process may be expressed in terms of a 
reversible bimolecular reaction on the basis of the law of 
mass action, by the following equation:<7>
6
VAg + A b  AgAb
K2
where Ag = antigen, Ab = antibody, and k x and kz are the 
rate-constants of the forward and reverse reactions. 
According to the law of mass action, the following 
relationship holds:
K = iii = CAgAb3
k3 CAg 3 C Ab 3
where K is the equilibrium constant. Thus it can be seen
that the concentration of antigen, the concentration of
antibody and the combining capacity of the antibody affects
the primary Ag—Ab reaction. The quantitative nature of
antigen—antibody reactions was first exploited by
Heidelberger and Kendall <f3> in 1935. Their results led to
the postulation that the formation of immunoprecipitates,
the so-called secondary reaction, is based on a series of
bimolecular reactions following the law of mass action:
Ag + Ab ■—  v. AgAb
Ag—Ab Ab----- -^--- Ag— (Ab)= (antibody excess)
and larger aggregates
or Ag—Ab + Ag-Ab r   (Ag) 2 — (Ab) 2  etc.
forming large aggregates when " concentration ratios of 
antigen and antibody are at or near equivalence. These 
secondary reactions proceed since both antigens and 
antibodies are at least divalent, with antigens usually 
being pentavalent.
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1-1-1 Non—labelled Immunoassays
In 1897 Kraus showed that soluble macromolecular 
antigens combined with antibodies to -form a precipitate. It 
was as late as the 1930's however before the above reactions 
were studied in detail. Heidelberger and Kendall<s> (1935)
were the first to report a quantitative determination of 
protein by the immunoprecipitin technique. They isolated and 
estimated the immunoprecipitate formed by adding increasing 
amounts of an antigen to a fixed amount of antibody. The 
amount of precipitated complex increases with rising 
quantities of antigen up to a certain point. This region of 
increasing precipitation is referred to as the antibody 
excess zone. Above this point there is no further increase 
in precipitated complex, where a degree of equivalence 
exists between the two reactants, termed the zone of 
equivalence. With increasing quantities of added antigen, a 
zone of inhibition of complex formation is reached (antigen 
excess); here, there is a progressive decrease in the amount 
of antigen—antibody complex precipitated. This pattern of 
reaction, shown clearly in Chapter 3, is characteristic of 
the immunoprecipitin technique since both Ag and Ab are at 
least divalent, and at equivalence a precipitating Ag—Ab 
lattice is formed.The immunoprecipitin reaction is dealt 
with more fully in Section 3.2.3.
Methods are available for the qualitative and 
quantitative analysis of both single antigens and antigen 
mixtures, and for monitoring the chromatographic separations
8
(electrophoresis)of serum samples- In mast cases the assays 
are not carried out in -Free solution, but within the pores 
of a gel, typically agarose- This approach provides a means 
of controlling the anti gen—antibody reaction and facilitates 
the use of small sample volumes (1—5 p.1 > - It also offers 
tests in which the resolution is increased by initially 
performing a separation procedure on the sample 
(immunoelectrophoresis) followed by an immunological 
reaction, where the separated antigens form precipitates 
with their specific antibodies- In some methods, e.g., the
Mancini immunodiffusion techni que<s>> for the quantitative 
determination of a single antigen, a gel which is uniformly 
impregnated with antibody is used. A standard volume of 
antigen (sample), when placed in the antibody impregnated 
agar will diffuse into the surrounding gel, where the 
resulting combination of antigen and antibody will be
revealed as a ring of precipitate. At equilibrium (after 
approx. 4S hours) the diameter or area of the precipitate is 
related to the amount of antigen in the sample. The Mancini 
technique finds widespread use in clinical laboratories for 
the quantitative determination of human serum proteins.
Further advances in gel techniques have led to the 
development of the Laurel1 technique410* and the technique 
of counter immunoelectrophoresis 1 x x * (CIEP). Both these 
techniques provide quantitative information on the
components of complex mixtures of antigens- Injection of
such a mixture into an animal produces a polyspecific
9
antiserum, which contains antibodies capable of reacting 
independently with each antigen- In the analysis o-f mixtures 
o-f antigens (e.g. whole serum) a simple zone electrophoresis 
is -followed by a second electrophoresis, perpendicular to 
the first, into an antibody containing gel. Individual 
antigens form 'rocket' shaped peaks. CIEP, however, 
increases the sensitivity and the rate of the 
immunoprecipitin reaction in gels. In this assay, antigens 
do not diffuse randomly, but are electrophoresed in 
ion—agar, i.e. sample and antibody are forced towards each 
other by electrophoresis at pH=8.6. The sensitivity may be 
further increased by adding poly(ethylene glycol) to the 
agar so as to enhance precipitation of immune complexes<12>.
When antigen—antibody complexes form in solution, even 
at very low concentrations, they can be detected by light 
scattering 413> and turbidimetric <1‘*> techniques. The current 
importance of the immunoprecipitin technique for the 
analysis of plasma proteins has been emphasised by the 
development of an automated immunoprecipitin analyser (AIP) 
by Ritchie<iS>. This instrument, based on the Technicon 
continuous flow analyser, is capable of processing over 100 
samples hour"1 in a multi-channel mode. The subsequent use 
of laser nephelametry to increase the sensitivity of the 
method <1<s> further attests to its current importance. Many 
workers have reported the immunological determination of 
human immunoglobulins with a centrifugal analyser. By 
utilising this method both equilibrium and kinetic
10
techniques have been used to quantify serum immunoglobulin G 
levels417*l0> (Section 3.3.1).
The attraction of the immunoprecipitin technique in 
solution, is that it is a simple technique which yields 
relatively fast analytical read-outs, and as such is readily 
automated. However a drawback of the technique is that it is 
relatively insensitive, but acceptable, for analyses of 
analytes whose normal concentration ranges are high (e.g. 
human serum IgG, range 600-1600 mg dl"1). The need for such 
readily automated homogeneous assays is illustrated by the 
ever escalating demand for immunoassays in clinical 
1aboratories, coupled with stringent reproducibility 
requirements<13>. Automation of a method significantly 
contributes to good precision and inter— laboratory 
correlation419’, since human intervention in a chemical 
analysis is minimized and thus an overall improvement in the 
control of the analysis is achieved.
1.1.2 Label1ed Immunoassays
The non-labelled immunoassay procedures discussed thus 
far are only applicable to proteins, and although simple and 
precise, they are relatively insensitive420’. In order to 
increase the sensitivity of these assays, isotopic and 
non—isotopic labelled immunoassays have been developed. 
Initial studies by Yalow and Berson421*22’ in 1959 involved 
the use of radioactive iodine as a label for the hormone 
insulin, and radioactive atoms are still the most commonly
11
employed labels in current methodology- In the method o-f 
radioimmunoassay a fixed amount of radio—labelled antigen 
(hapten) participates in a competitive binding reaction with 
unlabelled (sample) antigen and a fixed amount of antibody. 
The more unlabelled antigen present in the test sample, the 
less labelled antigen can bind to the antibody. Since the 
properties of the radiolabel are essentially the same 
whether the labelled antigen is bound or unbound, a 
separation step is necessary (after an appropriate 
incubation period), making the assay rather difficult to 
automate. However, there are automated RIA systems 
available, but these are very expensive and often require a 
separate laboratory in which to perform the assays- The 
separation methods usually employed are:
i) adsorption of the unbound antigen on charcoal or 
dextran-coated charcoal.
ii) the use of solid phase antibodies (i.e. immobilized 
antibodies), which bind the unbound antigen.
The radioisotopes used are generally the ^  -emitters 3H 
and14C, and the ^-emitters A==5I and
Radioimmunoassays are used in many clinical laboratories for 
the determination of hormones (e.g. thyroxine), drugs (e.g. 
barbiturates, steroids) and macromolecules (e.g. ferritin, 
thyroglobulin), assays in which the normal concentrations 
are in the nmol—fmol region and thus too low to be 
determined using precipitin techniques.
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Despite the excellent sensitivity o-f radioimmunoassay 
(R1A) , recent efforts have concentrated on replacing the 
radiolabel with a non—isotopic label. This is due to the 
many drawbacks o-f radiolabels. Preparation o-f the 
radiolabelled antigens or antibodies involves health risks, 
which are cumulative, the labelled protein shows 
batch—to—batch variation and generally has a shelf— life 
limited to two months. Separation of reacted from unreacted 
radiolabelled compounds is essential, and hence a 
heterogeneous type assay system is employed<23> .
Non—isotopic assays are popular because they avoid the 
need for the safety precautions and specialist equipment 
required for radiolabels. The methods may be homogeneous, 
and thus readily and easily automated. This result may be 
achieved by using a label whose properties change when the 
labelled protein is bound to its antigen/antibody. Among the 
non—isotopic labels used to date have been enzymes<24*2 S > , 
viruses<26>, metal ions<27>, free radicals <=so> , 
chemi luminescent and bioluminescent groups<2,?> , and 
fluorescent groups<30>; of these only enzyme labels and to a 
lesser extent fluorescent labels, are currently in use in 
clinical laboratories. The remainder of this discussion is 
confined to the use of enzymes as labels. A more thorough 
treatment appears in Section 4.1.
The advantages of using enzyme labels in immunoassay
are:
i) no radiation hazards occur during labelling or disposal
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o-f waste
ii) enzyme—label led products can have a long shel-f— li-fe 
e.g. one year
iii) equipment (e.g. spectrophotometers) for enzyme— 
immunoassay is inexpensive and generally available
iv> enzymes are biological catalysts. Since a single
molecule of catalyst can transform many molecules of
substrate to product by repeating the catalytic event 
over and over again, the catalyst (enzyme) acts in 
effect as an amplifier,
v) the final step of an enzyme immunoassay procedure is
basically the determination of enzyme activity, a 
procedure which is routinely used in many clinical 
laboratories.
Enzyme—immunoassay (ElA) is carried out via two main 
protocols:
i) Heterogeneous Enzyme—immunoassay
ii) Homogeneous Enzyme—immunoassay
The factors which govern the choice of enzyme labels 
for a particular application in EIA are listed in Table 1.1. 
The significant parameters are those which are derived from 
studies on the coupled enzyme—protein conjugate rather than 
on the native enzyme. These factors may differ depending 
upon the nature of the protein (e.g. molecular size, charge 
etc.), the number of sites of attachment and the coupling 
agent emp1oyed.
U
T able 1,1
Factors Affecting the Selection and Performance 
of Enzymes as Immunochemical Labels 
Criteria for Enzyme Selection
a) High specific activity at a suitable pH
b) A simple and sensitive detection must exist
c> Lack of inhibition by substances present in biological
fluids
d> Possess reactive groups through which it may be 
conjugated to other molecules
e) Retain its activity after the conjugation step
f) Be available in high purity at a reasonable cost
g) Stable under assay and storage conditions
h) Absence of endogenous activity in the sample
Heterogeneous EIA is an analytical technique that was 
originally reported by Van Weeman and Schuurs<31> and 
Engval1 and Perlmann<32}. The principles behind the various 
assay protocols are similar to those in which other labels 
are used- Competitive EIA is analogous to the classical RIA
c-
procedure described above- The choice of separation method 
in heterogeneous EIA is limited by the large size of the 
enzyme label as compared to the radiolabel, which precludes 
the use of methods which are commonly used in RIA such as 
charcoal separation. Separation methods employed include the 
use of second antibodies<33>, and the use of magnetic
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particles (paly— (acrylamide) beads impregnated with iron 
oxide) linked to either the antigen or a n t i b o d y . 
Heterogeneous ElA methods have, however, made most impact 
when such separation methods have been dispensed with. This 
great advantage has been realised by employing solid 
supports on which to immobilize either the antibody or the 
antigen.
the use of solid-supports in both competitive and 
non-competitive techniques was given the name Enzyme Linked 
ImmunoSorbent Assay (ELISA) by Engvall and Perlmann<32>. The 
solid support most -frequently used in ELISA is the 
polystyrene microtitration plate, which is cheap and 
requires only small volumes of reagents. Commercial 
availability of equipment now allows incubation, washing and 
direct 'through the plate' reading of absorbance. The final 
absorbance reading is due to the action of the enzyme label 
on a substrate solution which contains a chromophore. The 
absorbance of this solution may then be related to the 
initial amount of antigen present in the sample.
Homogeneous ElA - The Enzyme Multiplied Immunoassay 
Technique (EMIT) is the most widely used homogeneous enzyme 
immunoassay. The technique was introduced by Rubenstein et 
anci depends on a change in the specific enzyme
activity when antigen binds to enzyme labelled antibody. The 
activity of the unseparated assay mixture corresponds to the 
proportion of enzyme labelled antibody to which antigen is 
bound.
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The earliest EMIT systems <3 0 * employed lysozyme as the 
enzyme label. The natural substrate for this enzyme is the 
peptidoglycan linkage of the cell walls of certain bacteria. 
When lysozyme acts on a suspension of certain bacteria the 
turbidity of the suspension is reduced, thus providing a 
convenient measure of enzyme activity. Lysozyme—antibody 
conjugates are active with the bacterial suspension but when 
antigens bind to the enzyme-antibody conjugate, a steric 
barrier is presented to the bulky substrate. Antigen binding 
in this way can inhibit up to 98% of the enzyme activity. 
Thus, the more antigen present in the sample the more the 
inhibition of the enzyme activity, yielding a low absorbance 
value.
Thus both ELISA and EMIT are versatile methodologies 
designed to measure micro-amounts of analytes in test 
samples. A comparison of ELISA and EMIT is given in 
Table 1.2.
The major advantage of the EMIT system is that it can 
be automated with relative ease and produces rapid results. 
The commercially available 'kit' methods have been adapted 
for use with centrifugal analysers<3<s>> and continuous flow 
systems*3 7 ’.
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TABLE 1,2
Comparison of ELISA and EMIT Techniques
ELISA EMIT
Heterogeneous assay 
Reagent separation required 
(centrifugation or filtration) 
Reagent washings required
Slower than EMIT 
Sensitivity > EMIT 
Macromolecules measured 
(antigens, antibodies)
Solid phase assay
Homogeneous assay 
Reagent separation not 
required
Step washings not 
required
Faster than ELISA 
Sensitivity < ELISA 
Small molecules measured 
(haptens— e.g. drugs) 
Liquid phase assay
Automation of the two ElA procedures, ELISA and EMIT, 
using flow injection analysis is discussed in Chapter 4.
1.2 Flow Injection Analysis
The concept of flow injection analysis (FIA) was 
introduced in 1975 by Ruzicka and Hansen <3f3>, and is a 
technique based on unsegmented continuous flow. In its 
broadest context continuous flow analysis refers to any 
process in which the concentration of analyte is measured 
uninterruptedly in a stream of liquid. In the present 
context, successive samples pass through the same length of 
tubing in the analyser, reagents being added further
18
downstream, the mixing and incubation taking place while the 
sample solution is on its way towards a flow—through 
detector, where the signal is continuously monitored and 
recorded<3<?> . The main difficulty to overcome is the 
intermixing of adjacent samples during their passage through 
the analyser conduits. To minimize this so-called carryover, 
Skeggst“*°> introduced air segmentation, thus dividing the 
flowing stream into a number of compartments separated by 
air bubbles. The first system was designed for the 
determination of urea and glucose; the Technicon Auto 
Analyzer originally designed for this method has since 
become the most popular automatic analyser ever marketed.
By changing the concepts on which air— segmented 
continuous flow systems have been based, the technique used 
to perform continuous flow assays may be greatly simplified. 
FIA is based on the injection of a fixed volume of liquid 
sample into a non—segmented continuous carrier stream of 
reagent or buffer. The injected sample forms a zone, which 
is then transported towards a detector. The detector 
continuously monitors the absorbance, electrode potential, 
or other physical parameter which continuously changes as a 
result of the passage of the sample material through the 
f1ow-cel1 <3Q>. The simplest flow injection analyzer,depicted 
as a manifold in Figure 1.2a), consists of a peristaltic 
pump, which is used to propel the reagent/buffer stream (R) 
through a narrow tube (typically 0.5 mm id); an injection 
port, by means of which a fixed volume of a sample solution
19
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(S) is injected into the carrier stream in a reproducible 
manner; and a reaction coil in which the sample zone 
disperses and reacts with the components of the reagent 
stream, forming a species which is sensed by a flow-through 
detector and further recorded- A typical recorder output has 
the form of a peak ^ Figure 1.2b> , the height (H) of which
is related to the concentration of the analyte- The time 
span between sample injection (S) and the peak maximum, 
which yields the analytical read-out, is the residence time 
(T) during which the chemical reaction takes place.
FIA is founded on a combination of the following three 
principles <3,?> :
i) sample injection
ii) controlled sample dispersion
iii) reproducible timing of events
i) sample injection — The purpose of sample injection is to 
introduce a discrete 'slug' of sample into a continuously 
moving carrier stream- The amount of sample need not be 
known accurately but it must be introduced into the carrier 
stream precisely, so that the volume and length of the 
'slug' can be reproduced exactly from sample to sample- Thus 
automatic loading and subsequent injection of the sample 
into the carrier stream would have definite advantages over 
a manual approach and lead to improved precision.
ii) controlled dispersion - FIA has the purpose of analysing 
the maximum number of discrete samples using the minimum
21
amount of time, reagent, and sample solutions. With this in 
mind, sample zone dispersion (in the carrier stream) is 
controlled so that its degree — low to high — exactly suits 
the detection method and chemistry associated with it.
Dispersion, D, in the FIA system is defined as the 
ratio between the original concentration, C**, and the 
concentration of the dispersed species at the peak maximum, 
CmmM, which may be mathematically represented by:
D = C«=*
Cm*»
and is presented in Figure 1.3.
For convenience, dispersion has been classified as:
Dispersion used for
limited D<3
medium 3<D<10
large D>10
inherent property of the sample 
e.g. pH
chemical reactions e.g. colorimetric 
determination of phosphate as molybdenum 
blue<30>
FIA ti trations , and also sample 
dilution.
iii) reproducible timing — reproducible timing is of the 
utmost importance in FIA. The time from introduction of the 
sample into the carrier stream until it is detected is 
solely dependent upon the pumping speed and the dimensions 
of the post—injection coils.
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The ease with which the FIA system can be automated, 
together with the wide variety of detection techniques
available and already exploited by many workers, e.g.,
chemi 1 umi nescence J f 1 uori metry <^ =5> , spectro­
photometry <3e> , and p o t e n t i o m e t r y s u g g e s t  that FIA could 
provide an attractive, high throughput, low-cost alternative 
to other instrumentation currently used for the study of 
immunological reactions.
However, the FIA approaches considered above are less 
well suited to analysis in which the reagent is a biological 
macromolecule such as an antibody or enzyme, since these 
reagents may be costly and are often available only in small 
quanti ties . Two additional principles recently applied 
to FIA have, however, allowed for new applications of the 
technique. It has been shown<AQ> that stop—flow analyses are
feasible i.e. that the dispersion of a sample zone in the
carrier stream will remain constant if the flow rate of the 
stream is reduced to zero, while the reaction continues. The 
principle is of great value in kinetic assays'4*7’ . There are 
three different purposes for operating a FIA system in the 
stop-flow mode:
1) to increase the sensitivity of measurement by increasing 
the residence time (T), and thus the yield of the 
measured species
2) to measure a reaction rate which then serves as a base 
for the analytical readout.
3) to overcome a background signal from the sample.
24
If the sample zone is stopped Mithin the flow—cell
itself, it is possible to record the change of absorbance
caused by the reaction between the sample component and the 
reagent constituting the carrier stream- The obvious 
prerequisite for such a reaction rate measurement to be 
reproducible is that the movement of the carrier stream can 
be exactly controlled from the pumping rate used to complete 
standstill, and in this manner the same section of the 
sample zone can always be held reproducibly within the 
flow-cell for measurement. In practice, this is easily 
achieved by using a microcomputer to control the timing 
sequences of an assay as shown in Figure 1.4a. Thus, any 
delay-time, as well as any length of stop—time, can be 
chosen so that it suits the reaction rate of a particular
chemistry. The performance of a FIA system, for use in a
stop—flow mode, is illustrated in Figure 1.4b). The figure 
shows the profile obtained for a continuous flow measurement 
(curve A ) , and also for a stop—flow measurement of a sample 
containing no analyte of interest (curve B ) , the horizontal 
profile showing no reaction proceeding in the flow—cell. The 
dashed line (C> indicates a record one would obtain if a 
chemical reaction were taking place in the flow—cell, with 
the angle being dependent upon the reaction rate.
Rate measurements are often used in clinical 
chemistry, since the chemistries studied are often those in 
which a large equilibrium attaining time is required. Thus 
the enzymatic assay of glucose, based on the use of glucose
25
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dehydrogenase coupled to the spectrophotometric measurement 
o-f the co—enzyme NADH, became the -first chemistry
incorporated into a stop— flow FIA system .
In addition, economies in the use of reagent as well
as sample can be achieved by using the merging—zones
approach; small volumes of both sample and reagent are
injected into inert carrier streams and subsequently merge 
to allow clinical reaction before being carried to the
detector (see Figure 1.5). The merging—zones principle 
requires the use of a multi— injection valve which allows the 
simultaneous injection of the sample and reagent into two 
separate carrier streams pumped at the same speed which then 
meet in a controlled manner further downstream. As distilled 
water (or diluted buffer— detergent mixture) may be used as 
carrier in both streams, the reagent volume consumed per
determination may be 30 j^.1 or less. The carrier streams may
also be pumped continuously, for single—point measurements, 
or intermittently, for stop—flow rate measurements.
The merging—zone principle has been applied to a
number of analyses*30’ , including, in conjunction with the 
stop-flow principle, the enzymatic assay of serum 
glucose*4^ ’.
The application of FIA in the field of immunoassay was 
first reported by Lim et al in 1980, in which albumin
f
was determined by a homogeneous fluorescence energy transfer 
immunoassay. In this paper, the manifold used was of the
27
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stop— flow merging-zones type due to the advantages outlined 
above.
1.3 Aims and Objectives
The aim of the work reported in this thesis was to 
develop a versatile automated stop— flow merging—zones -flow 
injection analysis system, and to subsequently exploit the 
potential analytical advantages of the technique in the 
study of immunoassays. Immunoassays based on a number of 
methodologies such as immunoprecipitation and enzyme 
labelling are to be investigated, and their analytical 
potential in conjunction with FIA is to be critically 
assessed.
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2. DEVELOPMENT OF A FULLY AUTOMATED FLOW 
INJECTION ANALYSIS (FIA) SYSTEM
2 DEVELOPMENT QF A FULLY AUTOMATED FIA SYSTEM
2.1 Introduction
The need -for simple, cheap and easily automated 
techniques has resulted from the ever increasing sample
numbers and types submitted to laboratories for analysis 
each year. Many laboratories are faced with analysing small 
sample batches (10 — 100 samples) for a wide and varying
range of analytes. For such 1aboratories, a simple and
versatile system capable of handling small sample batches
rapidly would be of value. The technique of flow injection 
analysis meets the above constraints and also possesses a 
capability for minimum change—over time between chemistries.
The need for, and advantages of automation during this 
work may be clearly seen by reference to Chapters 3, 4, and 
5, especially work on stop—flow procedures, where the
reproducible timing of events is of the utmost importance.
2.2 Experi mental
A photograph of the home-made automated FIA system 
used during these studies is shown in Figure 2.1. The main 
components of the system are labelled A to M and are 
explained briefly in the Key (overleaf). Not in view in the 
photograph is the auto-sampler which was added to the system 
at a later date.
A block diagram of the fully automated FIA system 
which has been developed is depicted in Figure 2.2. The 
microcomputer, an Apple H e ,  is used to control the
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operation of a sample injection valve (home-made), the 
switching on and off o-f the peristaltic pumps (Ismatec—S840 
and Crouzet 42/81), the operation of an auto—sampler (Hook 
and Tucker T-40 sampler), the reproducible timing of events 
and the collection and treatment of data. The necessary 
accesories include an active interface board (Stack 
Computers 6522 VIA) with an on—board clock, a buffer chip 
(Farnell SN7416N) and solid state relays (Radio Spares 
346671) for control purposes and an analogue to digital, 
A/D, converter (Hewlett Packard 3438A; 3.5 digit) for data 
collection.
A schematic diagram of the hardware used to control 
the active interface is presented in Figure 2.3. The 6522 
Versatile Interface Adaptor (VIA) has 16 input/output 
channels, only five of which are used, and clock function 
capabilities. The five output channels are connected in such 
a way as to control a sample injection valve, two 
peristaltic pumps and the auto-sampler. Automated operation 
of the sample injection valve is achieved by connecting two 
of the solid state relays to two solenoid valves (50V), 
which in turn control the position of a double acting 
pneumatic arm (Economatics, Sheffield), which is attached to 
the injection valve. Thus, the sample injection valve relies 
upon gas pressure for its motive force and it is supplied by 
a nitrogen cylinder at a pressure of 50 p.s.i.. Another two 
solid state relays control the on/off action of two 
peristaltic pumps. Only when working in the merging zones
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mode are both pumps employed; one being used -for propelling 
the reagent/buffer streams and tor -filling the sample loop 
o-f the injection valve by attachment to the aspirator on the 
auto-sampler, the other being used exclusively -for -filling 
the reagent loop o-f the injection valve. Another solid state 
relay is connected to the auto-sampler, and upon receiving 
an output pulse from the computer the sample carousel is 
activated and proceeds to the next sample.
Raw data obtained -from the variable wavelength 
detector is -fed to a chart recorder and an A/D converter, 
and input into the microcomputer via a passive IEEE—488 
interface card. Raw data obtained in this way is stored on 
floppy disc (120K memory) a n d ’ processed on completion of a 
batch analysis.
In operation, the controlling software enables the 
sample injection valve to be placed in either the sampling 
load position or the inject position, the pumps to be turned 
on or off, the auto—sampler to be operated, and the 
collection and treatment of data. All of these parameters 
can be set independently and easily varied as required for 
different analytical programmes. Reproducible timing of 
these events is the major advantage of automatic operation, 
and is achieved (to 0.01 s) using the on—board clock of the 
VIA unit.
The software developed for the control of the 
automated FIA system is given in Appendix I, and is 
described by the flow—charts in Figures 2.4 and 2.5. The
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-flow-chart in Figure 2.4 describes the continuous—flow 
maximum peak height measurement option, which has only been 
of limited use in the study of immunoassays. This software 
could be employed in FIA systems such as the detection of 
sulphate (Section 3.2) i.e. with relatively fast colour 
(turbid) forming chemistries.
The flow-chart in Figure 2.5 describes a stop—flow 
kinetic measurement procedure, which has been the 
measurement/detection system used for the immunoassay 
procedures to be reported here. This system allows for the 
taking of two readings, with a pre-specified time increment, 
from which the rate of reaction is calculated in absorbance 
units min-1. The rate value calculated is then processed in 
the statistical package at the end of a batch analysis.
The software d e v e l o p e d  i for the statistical analysis of 
the raw data iS V sft&ftdojrcL ' and has routines for the
calculation of:
(1) mean, SD, and 7CRSD
(2) regression analysis for 'n' specified points
(3) second order fit for 'n' specified points
(4) interpolation of unknown concentrations from (2) and (3) 
above.
Thus, on completion of a batch analysis the microcomputer 
processes the raw data and the final output is obtained on a 
printer (Epson FX-82). The final print—out includes:
(1) parameters for the analysis
(2) raw data collected
42
(3) mean, SD, and XRSD -for each standard value
(4) linear regression and second order closeness of -fit
(5) raw data and interpolated values for unknowns from both 
linear and second order fits.
The performance of the automated system was initially 
monitored during its development using the turbidimetric 
determination of sulphate. The manifold design and reagents 
were as described in Section 3.2. Table 2.1 shows the TiRSD 
values (5 repeats) for a range of sulphate standards 
(0— 100 ppm) when using the FIA system in various stages of 
development. 7CRSD < 1) corresponds to a completely manual FIA 
system whereby the operator loads the sample , controls the 
action of the injection valve and gathers and processes the 
data. As expected the 7CRSD values are large for all standard 
values. XRSD(2) corresponds to a semi—automated FIA method 
whereby the only process involving the operator is the 
loading of the sample into the injection valve. A 
corresponding decrease in all the XRSD values shows that the 
system is now more sensitive, due to the automatic control 
of events. XRSD(3) corresponds to a fully automated system, 
where there is no operator intervention, and the 
reproducible sequencing of events contributes to an increase 
in performance of the system. Thus, the monitoring process 
has clearly shown that the automation of a system/technique 
not only minimises operator error and involvement but also 
significantly increases the reproducibi1ity of the results.
^3
TABLE 2.1
Development o-f an Automated FIA System using 
the Determination o-f Sulphate as a Model
Concentration Absorbance
Std / ppm__________  Mean_______7.RSD (1) 7.RSD (2) 7.RSD (5)
0
20 -0018 22.0 4.9 2.6
40 .0071 14.0 8.0 4.1
60 .0148 6.0 4.0 2.2
80 .0239 5.0 4.0 3.0
100 .0317 5.8 5.7
kk
3. DEVELOPMENT'OF A TURBIDIMETRIC IMMUNOASSAY 
PROCEDURE USING FLOW INJECTION ANALYSIS
3 DEVELOPMENT DF ft TURBIDIMETRIC ASSAY USING FIft
Three turbidimetric assays were studied, commencing 
with two model systems and -finishing with a 'real' 
immunoassay - the determination of serum immunoglobulin S. 
The two model systems employed provided problems of 
increasing complexity which served to aid the development of 
expertise, and the experimental system to be employed in 
future work. The three assays are discussed in order of 
increasing complexity.
3.1 Determination of Sulphate 
-3.1.1 I ntroducti on
Preliminary studies on the FIA system and the possible 
use of turbidimetry as a viabje detection method were 
carried out using the determination of sulphate as barium 
sulphate. The measurement of the turbidity of a barium 
sulphate suspension is well known as a standard method for 
the determination of sulphate in natural waters and has also 
been used for the determination of sulphur in soils and 
p1 an ts(1 * .
Sulphate has recently been determined using FIA, 
typically in the range 10— 140 ppm. The method of Krug et 
al_<:2> formed the basis of the work reported here. Krug 
and his co—workers used an acidic carrier stream of barium 
chloride di hydrate (5/i w/v) plus poly (vinyl alcohol) (0.05/i 
w/v), into which aqueous sulphate standards in the range 
10-200 ppm were manually injected. By optimising conditions
h5
such as flow rate, sample volume, reagent. stream 
concentration and length of post injection mixing coils they 
developed a system capable of handling up to ISO
samples h— *.
Other workers have also developed FIA techniques for 
the determination of sulphate. For example, Baban <3) 
modified the above method by using an alkaline barium—EDTA 
carrier stream into which an acidic sulphate sample was 
injected. In the acidic medium, i.e. the sample zone, 
precipitation of barium sulphate will occur. In an excess of 
the alkaline EDTA carrier stream, however, the residual 
precipitate will re-dissolve, thus keeping the system clean.
Kondo et_al_<4> proposed a flow injection method 
for the determination of sulphate in river waters, based on 
the decolouration of the barium dimethyl—sulfonazo— III 
complex carrier stream measured spectrophotometrically at 
662 nm.
3.1.2 Experi mental
Reagents
The carrier stream consisted of an acidic <0.1M HC1> 
solution of barium chloride dihydrate (57. w/v) (BDH) plus 
poly(vinyl alcohol) (0.05a w / v )  (BDH).
The sulphate standards were prepared from a 1000 ppm 
(SO,*3-) stock solution of sodium sulphate.
Apparatus
The FIA system used in these experiments was a 
manually operated manifold as described in Chapter 2,
whereby sample loading and injection and the collection and 
treatment o-f data were at the operators control. The 
sulphate system described below was then used to monitor the 
performance o-f the FIA system in various stages o-f its 
development.
3.1.3 Continuous—FIow FIA
In our studies, a mani-fold similar to the one used by 
Krug et al_<2> and depicted in Figure 3. 1 was used;
(Manifold (A)).
A peristaltic pump propelled the reagents to a 
pre—injection coil (polypropylene tubing, 0.5 mm i.d.) via a 
perspex T—piece which ensured thorough mixing o-f the 
reagents. Poly(vinyl—alcohol), PVA, was added to the carrier 
stream as a 'conditioning agent'. The PVA acts as a 
protective colloid and thereby prevents the rapid settling 
o-f barium sulphate particles and therefore gives more 
reproducible results. Using the home-made PTFE rotary
injection valve, 30 pi of sulphate standards (range 0— 100
ppm) were injected using a plastic syringe. The 
post—injection coil (polypropylene tubing, 0.5 mm i.d.) 
allowed for the reaction to develop with the transient 
signal obtained being monitored at 480 nm.
The results obtained from Manifold (A) are shown in 
Table 3.1. The rather high values of percentage relative
standard deviation (XRSD) show the inherent difficulty of
obtaining reproducibi1ity with turbidimetric detection. The 
system described suffers severely from base-line drift due
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TABLE 3.1
RELATIONSHIP BETWEEN SULPHATE CONCENTRATION AND TURBIDITY
OBSERVED WITH MANIFOLD (A)
All results are means o-f 5 experiments
Sulphate Absorbance
conc. (ppm) ______Mean___________ SD________  XRSD
0 0 0 0
10 0 0 0
20 0 0 0
40 0.0085 0.0018 21.2
60 ' 0.0171 0.0024 14.0
80 0.0251 0.0029 11.5
100 0.0322 0.0025 7.7
49
to the f'- o-F precipitate on the -flow—cell windows,
and -from a poor limit o-f detection (typically 30 ppm).
The problem o-f a dri-fting base-line was partially 
overcome by adding a -faster flowing reagent stream prior to 
detection in order to 'flush' the precipitated product 
(BaSCU) through the flow-cell, as shown in Figure 3.2, 
Manifold (B) . The results obtained with Manifold (B) are 
given in Table 3.2. Improved sensitivity and precision are 
evident. The increase in sensitivity with Manifold (B) may 
be attributed to the increase in total flow rate to
4.1 ml min-1, at the second T—piece, thus creating greater 
turbulence in the system and ensuring thorough mixing 
between the reagent stream and the sample zone. This ensures 
an increase in the amount of detectable, turbid barium 
sulphate solution produced for identical concentrations of 
sulphate standards as compared with the situation when using 
Manifold (A). It thus follows that incomplete mixing of 
sample zone and reagent stream occurs with the configuration 
depicted in Manifold (A). The faster flowing reagent stream 
is therefore beneficial in keeping the system clean and 
increasing the turbulence, thus ensuring thorough mixing of 
reagent and sample.
Further work carried out using Manifold <B) included 
the use of automatic sample loading and injection (see 
Chapter 2) and an increase in sample volume (100 y\l) , both 
of which contributed to improved sensitivity.
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TABLE 5.2
RELATIONSHIP BETWEEN SULPHATE CONCENTRATION AND TURBIDITY
OBSERVED NITH MANIFOLD (B?
All results are means o-f 5 experiments
Sulphate Absorbance
conc. (ppm)__________ Mean__________ SD___________XRSD
0 0 0 0
10 0 0 O
20 0- 0032 O- 0005 15.7
40 0.0106 0.0013 12.3
60 0.0213 0.0009 4.2
80 0.0319 0.0016 5.0
100 0.0449 0.0019 4.0
52
3-1-4 Conclusions
The sulphate system described here served as a model 
system to -familiarise the worker with possible problems that 
could be encountered in FIA with turbidimetric detection, 
prior to the use of costlier reagents- The major 'problem 
encountered in developing the sulphate system was that of a 
drifting base-line due to the ■: '' of the flow through
cell windows and the inherrent problems of reproducibility. 
These were succesfully minimised by the introduction of a 
faster flawing reagent stream just prior to the detector 
which ensured the thorough mixing of sample and reagent and 
prevented CCd t i t i a  , of the flow through cell windows.
53
3.2 A Model Immunoprecipitin Reaction
3.2.1 Introducti on
The model system studied was the precipitin reaction 
between concanavalin A (model antibody), a globulin 
extracted from jack bean meal, and yeast mannan (model 
antigen), a highly branched homopolysaccharide possessing 
^-D-mannopyranosyl units. Concanavalin A (con A) is one of 
the best known of the plant agglutinins, being first 
isolated and crystallised by Sumner and Howell455* in 1936. 
This lectin exhibits a series of properties which have 
resulted in a wide variety of applications. These include 
its use as a structural probe for carbohydrates in 
solution4*0 , as a reagent for differentiating normal from 
malignant cells47* , as an anti—cancer agent40* and, more 
importantly in the context of this work, in its selective 
interaction with the linkages of carbohydrates containing 
multiple x— D—mannopyranosyl , o'—D-glucopyranosyl and oc—D— 
fructopyranosyl units, as a model for the antibody—antigen 
reaction49*10*. It is also interesting to note that a novel 
immuno—electrode composed of concanavalin A covalently 
attached to a poly(vinyl chloride) membrane has been 
constructed, and shown to be capable of sensing 
yeast—D—mannan411 *12>.
Yeast mannan (gum) was one of the first 
polysaccharides reported to precipitate with concanavalin 
A 413*. Cifonelli and Smith later confirmed this with a 
turbidimetric assay for yeast mannan41'**. They incubated
54
1 mg of yeast mannan with an aliquot of concanavalin A to 
produce a turbid solution which was measured at 420 nut. From 
precipitin studies on a large number of polysaccharides, 
Goldstein ‘ 1S> suggested that only branched polysaccharides 
having multiple terminal <non—rebucing> x—D-glucopyranosyi 
and D—mannopvr anosy 1 groups would precipitate with
concanavalin A in a manner analogous to the immunoprecipitin 
system. This work follows on from previously reported 
preliminary studies ‘ 1&> for the determination of yeast 
mannan using the precipitation reaction with concanavalin A 
by stop—flow merging zones FIA. A full account of this work 
was recently pub 1 i shed c * .
3.2.2 Experimental 
Reagents
An aqueous buffer solution containing sodium acetate 
<10 mii) , sodium chloride <0.1 M) and Brij—35 <0.37. w/v) was 
adjusted to pH 6.2 with acetic acid (1 M).
Concanavalin A (Fluka) was reconstituted in the above 
buffer solution <2 mg ml-'1) (model antibody).
Yeast mannan (Sigma) standards were prepared in the 
above buffer solution over the range 0— 10 mg mi 1 (model 
antigen).
Apparatus
The static experiments were performed using a 
m icroprocessor controlled uv—visible spectrophotometer 
(Perkin-Elmer 5503) and micro glass cells (Heilma 
6082-Green), hicro glass cells, 0.5 ml volume, were used in
55
these experiments in order to ensure minimum consumption o-f 
expensive reagent (model antibody).
1 he FIA s'/stem employed in these experiments was as 
described in Chapter 2.
The model immunoprecipitin reaction was studied by 
adopting three procedures, each o-f which is described in 
detail below.
3.2.3 Static Experiments
These were performed in order to locate the zone of 
equivalence, to establish the optimum wavelength for 
monitoring the resulting turbidity, and to find a suitable 
reaction time (i.e. relatively slow reaction) for the flow 
through method described below. The term zone of
J
equivalence* is best understood by examining the generalised 
form of the immunological precipitation reaction which is 
shown in Figure 3.3.
As increasing amounts of multivalent antigen are
added to a fixed amount of at least divalent antibody, the
quantity of antibody precipitated increases. After the
addition of small amounts of antigen, some precipitate is 
formed, and free antibody is detectable in the supernatant - 
this is the antibody excess zone. The addition of further 
amounts of antigen results in increased precipitation until 
a point is reached where no free antibody or antigen is 
detectable in the supernatant. This is the zone of 
equivalence. Harrack410> hypothesised that at this point
optimal proportions of antibody and antigen form a
56
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continuous, stable antibody-anti gen lattice', whose
molecular weight increases steadily throughout the antibody 
excess region, and at this point reaches a maximum. At high 
levels of antigen, some antigen appears in the supernatant 
and at the same time precipitate formation is still maximal. 
This is the first stage of the antigen excess zone. At 
conditions of extreme antigen excess, the amount of 
precipitate is markedly reduced, due to the formation of 
soluble complexes- Solubilization of the lattice results 
from the excess free antigen competing for the antibody 
sites in the precipitate with the subsequent formation of 
soluble complexes47’.
Equal volumes (0.2 ml) of concanavalin A and a range 
of yeast mannan standards were manually mixed in the micro 
glass cells (by inverting twice) and the resulting turbidity 
of the solution monitored in the range 280—520 nm.
A wavelength scan for concanavalin A, yeast mannan and 
the resultant precipitin complex showed that turbidimetric 
detection at 400 nm gave the most sensitive response for the 
complex with no background absorption or scatter from the 
reactants. A typical set of results for measurement of the 
resultant turbidity at 400 nm, after 60 s reaction time, for 
a range of yeast mannan standards is tabulated in Table 3.3.
The results using concanavalin A (2 mg m l '1) clearly 
show the zone of equivalence, in the region 0.5 mg mi A 
yeast mannan. Of importance is that part of the precipitin 
curve where the antibody is in excess because there is a
58
TABLE 3.5
Yeast Hannan Concentration versus Turbidity using  ^
Spectrophotometer (F.E. 5503)
All results are means o-f -five experiments
Yeast Mannan Turbi di ty
(mg ml A) (absorbance units)
0 - 0 0.000
0.1 0.912
0.2 1.208
0.3 1.400
0.4 1.568
0.5 1.680
0.7 1.216
1.0 0.512
i . 5 0.2S0
2.0 < J . 216
Stati c
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quantitative relationship between antigen (analyte)
concentration and turbidity. Ail assays are thus carried out 
in the antibody excess region, whereupon a linear (or 
near-linear) relationship exists between antibody and the 
concentration o-f the analyte antigen- By varying the 
concentration o-f the antibody used, the region commensurate 
with antibody excess may be varied as to ensure this. 
Clearly, it is therefore important to be able to distinguish 
between conditions o-f antibody excess and antigen excess, 
since two concentrations o-f antigen give rise to the same 
signal- This is not possible when carrying out static 
experiments, but it is clearly seen when using FIA.
The immunoprecipitin assay was studied using two 
di-f-ferent FIA methodologies in order to ascertain their 
relative merits -for immunoassay procedures. By using a 
merging zones approach the amount o-f reagent used per assay 
is minimal whereas using a single channel mode the 
conditions o-f antibody excess and antigen excess may be 
clearly distinguished.
3.2.4 Stop-Flow Merging Zones FIA
The static method described above was adapted to FIA 
using a merging zones manifold as shown in Figure 3-4. The 
two buffer streams were pumped at 0.5 ml min~1 , using a 
peristaltic pump, through polypropylene tubing (0.5 mm
i.d.). Concanavalin A (30 ;.il ) and yeast mannan (30 p.1 ) were 
simultaneously injected into separate buffer streams using 
an automated home-made PTFE rotary injection valve (see
60
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Chapter 2 for details). Further downstream the concanavalin 
A and yeast mannan zones were synchronously merged at a 'T'
piece and then passed through a short mixing coil into the
flow through cell of the detector. The turbidity was
constantly monitored at 400 nm and the output fed to a chart 
recorder and an A/D converter- The rate of reaction was
determined by stopping a segment of the merged sample and
reagent zones in the flow cell and performing a simple 
two—point kinetic analysis. This was achieved by switching 
off the peristaltic pump 14 s after sample injection, 
measuring the turbidity 30 s and 60 s later, and then
re—activating the pump to flush out the reaction mixture. 
The delay time for switching off the peristaltic pump was 
determined by injecting bromothymol blue into the carrier 
streams and noting the time from injection to the peak
maximum- A calibration curve of yeast mannan concentration 
versus reaction rate (absorbance units min_i) was then
constructed at the end of each batch analysis.
A typical set of results for the merging zones 
sfcop-flow procedure is given in Table 3.4. The zone of 
equivalence (in the region of 0.5 mg mi*-1 yeast mannan) is 
clearly seen from a graphical presentation of the data
(Figure 3.5).
The '4RSD values (each from 5 replicate samples) are 
acceptable (<10/i) for a turbi dimetr i c analysis although both 
precision and sensitivity could be improved by a longer 
analysis time and a multi—point kinetic calculation
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TABLE 3.4
Yeast. Mannan Concentration versus Turbidity using a 
Stop-Flow Merging Zones FIA Manifold
All results are means o-f five experiments
Yeast Mannan_______ SI ope Standard Deviation RSD
(mg ml~ 1) (absorbance units min"1)
0.0 0.0001 0.0006
0.05 0.006 i O .0010 16.4
0. 1 0.0449 0.0059 13. 1
0. 0.1758 0.0069 3.9
0.2658 0.0148 5. 6
0. 4 0.2943 0.0087 3. u
O. 5 0.2966 0.0143 4. 8
0.7 0.2505 0.0 i 27
1. 0 0.1694 0.0124 10. 3
O 0.0556 0.0081 14.6
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(assuming that the slope of the rate curve is linear). The 
correlation coe-f-f icient -for the analytically important 
antibody excess region was 0.9808 -for the relevant (i.e. 
antibody excess) data (0-0.4 mg ml A yeast mannan).
3.2.5 Stop-Flow Single Channel FIA
For these experiments the FIA manifold was modified to 
a single stream containing concanavalin A pumped at 0.5 ml 
min~* as shown in Figure 3.6. Yeast mannan standards were 
injected into a stream of concanavalin A (2mg ml~1) and 
passed through a short mixing coil before reaching the 
detector.
The major disadvantage of this manifold design is the 
continuous consumption of a potentially expensive reagent 
(concanavalin A/antibody). On the other hand the advantage 
is that the results clearly distinguish between conditions 
of antibody excess and antigen excess. As the injected 
sample zone (yeast mannan) travels through the mixing coil, 
physical dispersion in the carrier stream (concanavalin A) 
occurs, and this results in a continuous sample 
concentration gradient from zero to some maximum value 
within the mixing coil. If assays were carried out using a 
continuous flow manifold and conducted in the region of 
antibody excess, the detector response would be in the form 
of a single peak, with a maximum at the point of maximum 
sample concentration. In the region of antigen excess 
however, the output would be in the form of a double peak 
with a trough at the point of maximum sample concentration.
6 5
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ihis is due to their being two -favourable concentration 
ratios -for maximum precipitin -formation within the 
concentration gradients set up in the mixing coil, one prior 
to the point o-f maximum sample concentration and one after. 
At the point o-f maximum sample concentration the condition 
o-f antigen excess prevails, which is therefore unfavourable 
for maximum precipitin formation, and thus a trough in the 
read-out is obtained.
In order to enhance the sensitivity of the single 
channel approach a stop flow technique was used, with a 
delay time of 10 s and a two point kinetic measurement 20 s 
and 50 s later- This delay time ensured that the zone of 
maximum sample concentration was located in the flow cell at 
the time measurements were made- The results are tabulated 
in Table 3-5 and, as expected, show an increased sensitivity 
compared with those obtained using the merging zones
manifold. In this instance the conditions of antigen excess
are indicated by a 'spike' in the output when more 
favourable concentration ratios for precipitin formation are 
swept through the flow cell on re—activating the pump. The 
'spike' originates from the second peak maximum as 
obtained .(A the continuous flow system described above- While 
the rate measurements were being conducted in the flow—cell, 
a more favourable concentration ratio for maximum precipitin 
formation was located in the mixing coil prior to the
detector. Upon re-activating the pump, this zone of maximum
6 7
TABLE 3.5
Yeast Mannan Concgntration versus Turbidity using a 
Stop—Flow Single Channel FIA Manifold
All results are means o-f -five experiments
Yeast Mannan_________ Si ope Standard Deviation RSD
(mg ml-1) (absorbance units min 1) (7.)
0.00 —0.0038 0.0020 —
0.02 0.0189 0.0011 5.8
0.05 0.2071 0.0061 2.9
0.07 0- 3573 0.0216 6.O
0.10 0.5401 0.0091 1.7
0.15 0.7941 0.0091 1.1
0.20 0.9318 0.0295 3.2
0.40 1.0560 0.0806 7.6
0.50 1.1576 0.1633 14.1
0.70 1.0941 0.2048 18.7
1.00 0.5562 0.1030 18-5
2.00 0.2527 0.0208 8.2
4.00 0.1045 0.0105 10.0
6 8
precipitin -formation was swept through the flow—cell, and 
appeared as a sharp increase in absorbance.
The above technique would be advantageous in 
circumstances requiring only a qualitative answer to a 
particular assay (i.e. is the concentration of the analyte 
greater than the normal expected concentration). By using an 
appropriate dilution of the antibody, the system may be 
adjusted so that samples with an abnormally high 
concentration of analyte will yield a spike on the chart 
recorder output. Thus, this method provides scope whereby 
samples may be rapidly screened for abnormally high antigen 
values.
3.2.6 Conclusions
The successful assay of yeast mannan has been 
performed using a stop—flow merging zones manifold. Using 
the conditions described, yeast mannan may be determined in 
the range 0-0.4 mg ml-1 yeast mannan with a quantitative
result available 90 seconds after injection. Precision of 
the method is acceptable for a turbidimetric analysis with 
XRSD values (each from 5 replicate samples) of 57. and an 
acceptable sample throughput in the order of 40 samples per
hour. By using a merging zones manifold the consumption of
reagent is minimised to 30 i^l sample-1.
The successful assay of yeast mannan has also been 
performed using a stop—flow single channel manifold. Using 
the conditions described yeast mannan may be determined in 
the range 0-0.4 mg ml-1 yeast mannan with a quantitative
69
result available 60 seconds after injection. Improved 
precision is observed with 7.RSD values (each -from 5 
replicate samples) less than 4/1 -for the relevant data and a 
sample throughput o-f 60 samples an hour.
The advantage o-f working in the stop-flow merging 
zones mode is that consumption of expensive reagent is 
minimised to 30 j j . 1 for each sample, and as a consequence the 
cost per assay will be low.
The advantage of working in the stop—flow single 
channel mode is that precision is improved and that 
conditions of antibody excess and antigen excess are easily 
distinguishable. The second point is of importance for 
setting up rapid screening procedures whereby conditions of 
antigen excess indicate a certain abnormal condition.
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3.3 Determination of Human Serum Immunoglobulin G (IgG)
3-3.1 Introducti on
The immunoglobulins are a group o-f structurally 
related plasma proteins which mediate circulating antibody 
responses'19’. They account for approximately one—seventh of 
the total serum proteins in normal adults<30>. Both 
antigenically and electrophoretically, the immunoglobulins 
are a highly heterogeneous group of proteins within any 
individual and also show common variability between 
individuals. There are five classes of immunoglobulins in
human blood plasma — IgA, IgD, IgE, IgG and IgM — of which
the IgG globulins are the most significant, making up about 
80% of the total in man'2 1 *2 2 ’.
Isolated human IgG is a monomeric protein of 
RMM 146000, consisting of two identical large ('heavy'(H)) 
chains having about 430 amino acid residues, and two 
identical smaller ('light' (L)) chains having about 214 amino 
acid residues. The two heavy chains are covalently linked by 
two disulphide bridges and each heavy chain is bound to a 
light chain in a similar manner as shown schematically in 
Figure 3-7. The heavy chains contain a covalently bound 
oligosaccharide component designated —CH0. Each chain has a 
region of constant amino acid sequence and a region in
which the sequence varies from host to host- The antibody
molecule has two binding sites for the antigen (the 
N-terminal ends of both the H and L chains) and the variable
71
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portions o-f the H and L chains contribute to these binding 
sites.
The serum IgG concentration in normal healthy adults 
lies within the range 600-1600 mg dl~1<;=3>. Depressed or 
elevated IgG levels are useful diagnostic indicators for 
various conditions. Depressed IgG levels are due to 
hypogammaglobulinaemia and protein loosing diseases e.g. 
nephrotic syndrome. Depressed IgG levels are also common in 
patients with malignant diseases, particularly of the 
haemopoietic system and immune systems. Low IgG levels are 
also encountered in paediatrics, especially the new born, 
since the infant is unable to produce its own IgG until 
about the twentieth week of life. During the interim period 
the maternal IgG's, which cross the placenta during 
pregnancy, are responsible for the immune defence of the 
child. It is not until the child is seven years old that 
its IgG level is indistinguishable from that of adults.
Serum IgG levels are elevated in a variety of 
bacterial, parasitic, and chronic infections e.g. in the 
tropical diseases malaria and kala-azar. An elevation is 
also observed in hyperimmunization and autoimmune disorders 
e.g. systemic lupus erythematosus, and rheumatoid arthritis, 
a condition characterised by inflammation and deformity of 
joints and which occurs mainly in elderly people, especially 
in the joints of limbs and the spine.
Concentrations of IgG in human serum are frequently 
estimated by immunochemical methods based on the
73
precipitation of ant i gen-anti body complexes in agar— gel .
imftiwo
One such technique, that o-f single radi al/v di-F fusi on (RID), 
is now widely used- This method was originally described by 
Mancini <==s> in 1965 and many modifications are presently in 
use. Solutions of antigens (serum) are introduced into small 
wells cut into the agar plates in which anti serum is 
uniformly distributed. Antigen diffuses from these wells and 
produces circular areas of precipitate. In practice the 
square of the diameter of the ring is usually linearly 
related to antigen concentration when diffusion has ceased — 
this is not usually complete for at least 48 hours. It is 
possible, however, to measure the ring of precipitate before 
its full development when the log of the antigen 
concentration is linearly related to the ring diameter{2<b> . 
Rings are usually less clear before completion and precision 
is therefore poorer. Although immunodiffusion is relatively 
simple to perform, requiring no sophisticated equipment, it 
suffers from a number of disadvantages. Accurate transfer of 
the small sample volume into the wells is difficult; the 
assay is very slow, requiring 24—72 hours for diffusion, and 
the diameter of the ring is difficult to measure accurately, 
and therefore precision is poor, giving coefficients of 
variation of +/— 20/l<31>.
Other gel immunoprecipitin techniques include: 
counter—immunoelectrophoresis (CIEP), where sample and 
antibody are forced together by electrophoresis at pH = 8-6; 
(this pH allows for the optimum mobilities of proteins in an
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electric -field) and Laurel! 'Rocket' el ectrophoresi 5, where 
a zone electrophoresis (separation of plasma proteins) is 
followed by a second electrophoresis, perpendicular to the 
first, into an antibody containing gel. Individual antigens 
form rocket shaped precipitates, the heights of which are 
proportional to the amount of antigen present*27’. The 
precision of this technique is somewhat better than that of 
RID, probably due to the greater ease of measuring a peak 
height rather than a ring di ameter <2:o> .
Since 1967 several laboratories have reported the use 
of light scattering and turbidity for the measurement of 
anti gen—antibody complexes formed in solution*217'30’ . These 
studies are based on the fact that particles such as 
cross-linked antigen-antibody complexes in solution scatter 
light to a considerably greater degree than free antigen and 
antibody. Further development of solution techniques has led 
to manual*31’ and continuous-f1ow nephelometric methods for 
the measurement of specific proteins*3 2 *33’.
The description of a fully automated nephelometric 
immunoassay system was presented in 1969 by Ritchie<3:2> . 
Efforts to improve the automated immunoprecipitin analyzer 
(AIR) produced an instrument capable of processing a variety 
of biological fluids in a multi-channel mode at the rate of 
over 100 samples hour-1, consuming small volumes of antigen 
and antibody, and yielding accurate results in the order of 
+/— 4 X  of the certified values for reference preparations.
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An important step towards improved sensitivity for
the method was made through the work of H e l l s i n g . He
showed that the immunoprecipitaticn reaction can be enhanced 
by the addition of a number of non—ionic polymers such as 
dextran, hydro:; y-ethy 1 starch or pol y (ethyl ene glycol) (PEG) 
to the reaction mixture. The most effective of these is PEG,
and as a result, all serum and antiserum dilutions were
carried out with an aqueous PEG solution in the FIA studies 
to be reported here. The mechanism of action of polymers in 
enhancing immunoprecipitation is generally accepted to be 
one of steric exclusion. In solution, a molecule will 
exclude all other molecules from the volume it occupies 
itself- The result of such exclusion is that the effective 
increase in concentration of antigen and antibody in 
polymer—containing solution results in the reaction :
Ag + Ab  ^ AgAb * (AgAb)n
being driven towards aggregation, i.e., the production of 
immune complexes and lattice formation. The result is that 
the polyanion markedly accelerates the rate of reaction and 
hence improves sensitivity.
In the AIP, based on the Technicon air—segmented 
continuous flow auto—analyzer, a serum sample is aspirated 
into the system through a pump tube. The sample enters an 
air-bubbie segmented stream of pre-diluted antibody. Gnce 
the sample has been introduced into the train of 
bubble-isolated antiserum segments, reaction with antibody 
commences. The time required in the manifold for light
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scattering to reach approximately 85/1 o-f maximum is of the 
order of 15 minutes. A delay coil, fixing incubation to the 
proper time, is inserted into the stream. Just prior to the 
flow—cell the bubbles that have insured the individuality of 
sub—samples are removed, leaving an uninterrupted stream of 
samp1e-wash-samp1e for optical analysis.
Many workers have adapted the immunoprecipitin method 
to centrifugal analyzers'3 3 ’3 6 ’ , where sample and reagent 
are mixed by centrifugal force. Nephelometric detection by 
both equilibrium end-point and reaction rate have been 
employed. By this method correlation with RID and AIR 
techniques are satisfactory'37’. Turbidimetric end-point 
readings for IgG are taken after 4 minutes, with the total 
analysis time for IgG being 9 minutes (which includes 
loading of tray).
One restriction to the widespread use of these 
instrumental techniques is the high capital and/or running 
cost involved. Also, a major disadvantage of the AIR system 
is the continuous consumption of expensive reagent 
(antiserum), coupled with the need for large sample batches 
to make it a viable proposition.
FIA has been shown to provide a cheap, rapid and 
automated analytical facility that is also flexible in its 
appl i cat i on '30 -3,7> . By using FIA, it is possible to further 
reduce consumption of expensive reagents by operating in the 
merging-zones mode'17’. The relatively slow immune complex 
formation times may be overcome by working in a stop—flow
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mode with the FIA system. It has already been shown that by 
using FIA it is possible to study a model immunoprecipitin 
reaction0 7 ’ (Section 3-2). It would therefore be 
appropriate for quantitative serum IgG determinations in 
clinical laboratories handling small sample batches 
(10— 100). The preliminary findings of this study have been 
pub 1 i shed <x*0> , and a fuller account has also been recently 
pub 1 i shed <'*1 y .
3.3.2 Experi mental 
Reagents
An aqueous solution of poly(ethylene glycol) (40 
g I-1) and sodium chloride (9 g l-1) was used for both the 
carrier streams in the FIA manifold and as the
serum/anti serum diluent.
Goat antiserum specific for human IgG, of
nephelometric quality (Atlantic Antibodies), was used as the 
antibody. The original solution contained sodium azide
(1 g preservative) and was evaluated for
monospecificity by immunoelectrophoresis. The working 
antiserum was prepared by diluting the goat antiserum
(0.3 ml) with PEG/NaCl diluent (24.7 ml) giving an 
approximate 80X dilution.
Human serum IgG standards were prepared by serial
dilution (500X— 1000X) of two human serum reference materials
(Atlantic Antibodies), with quoted values of 1778 mg dl_1 
and 3566 mg d l _1 IgG. A U.S. National Reference Preparation 
for Specific Human Protein (Centre for Disease Control,
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Atlanta), with a quoted value o-f 1128 mg dl-1 IgG, was 
diluted 800X and used as a control serum- Human serum 
samples were obtained -from Doncaster Royal Infirmary and 
diluted SOOX prior to analysis- All samples and reagents 
were stored at +4°C when not in use.
Apparatus
The apparatus used for the following experiments was 
as described in Section 3.2.2
3-3-3 Static Experiments
These were performed in order to locate the zone of 
equivalence, to establish the optimum wavelength for 
monitoring the resulting turbidity, and to find a suitable 
reaction time for the flow-through method described below.
A wavelength scan for the antiserum, a human serum 
standard and the resultant immunoprecipitin complex showed 
that turbidimetric detection at 340 nm gave the optimum 
signal to background ratio for the complex.
In order to determine the optimum dilution of the 
human serum samples and standards, equal volumes (200 jil) of 
antiserum and a range of dilutions (500X— 1000X) of the 
1778 mg d l ~ l human serum standard were manually mixed in a 
micro glass cell and the resultant turbidity monitored. A 10 
second delay time was used to allow for the mixing and the 
reaction rate monitored over the next 30 seconds at 340 nm. 
The resultant data is presented in Table 3.6. It shows that 
serum dilutions of 800X and more give rise to the condition
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TABLE 3.6
Turbidity versus Human Serum Standard (1778 mg dl~x)
Pilution
All results are means o-f two replicates
Serum Dilution Turbidity (A.U.)
1000 0.127
900 0-133
800 0.162
700 0.166
600 0-164
500 0-132
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o-f antibody (antiserum) excess and that a serum dilution of 
only 500X gives rise to the condition of antigen (serum) 
excess. As the concentration of the standard used was above 
the upper limit of the normal clinical range, a dilution 
factor of 800X was chosen for serum standards and samples in 
order to provide maximum sensitivity commensurate with the 
condition of antibody excess being met for the majority of 
samples. Equal volumes of serum and antiserum were used in 
the above experiments to facilitate the transfer of the 
reaction to a merging zones FIA manifold.
Having determined a suitable dilution factor to 
ensure antibody excess (800X), a range of human IgG 
standards (0— 1778 mg d l ~ M  were analysed by the above 
method. A typical set of results for the range of human IgG 
standards is given in Table 3.7, and shows a linear increase 
in absorbance over the range of IgG concentrations used. The 
correlation coefficient for the resultant calibration curve 
(Figure 3-8) was 0-9971, indicating that the top standard 
was within the antibody excess region and that the reaction 
conditions were suitable for a practical analytical method 
based on FIA.
3.3.4 Stop—Flow Merging Zones FIA
The manifold used for the FIA experiments is shown in 
Figure 3.9 and is a modified version of a previously 
described 5ystem<17> (Section 3.2.4). The two PEG/WaCl 
carrier streams were pumped at 0.5 ml min-1 through 
polypropylene tubing (0.5 mm i.d.). Working antiserum (30
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TABLE 5.7
Human Serum IgG Concentration Versus Turbidity 
using a Static Spectrophotometer
All results are means o-f 2 replicates
Concentrat i on Absorbance
Serum IgG mg dl~x
0 0
166 0.025
533 0.048
889 0.091
1155 0.114
1422 0.149
1778 0.169
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jjlI ) and human serum standards (800X dilution; 30 jjlI ) were
simultaneously injected into separate carrier streams using
the automated PTFE valve- Further downstream, the anti serum 
and serum zones were synchronously merged at a T—connector 
and passed through a mixing coil <20 cm) into the 
f 1 ow-through cell- To ensure complete mixing of the merged 
zones a close packed glass bead column (4 cm x 1-5 mm i.d.;
bead size 80 mesh) was incorporated into the mixing coil.
The turbidity was constantly monitored (340 nm) and the 
output -fed to a recorder and an A/D converter.
The rate o-f reaction was determined by stopping a 
segment o-f the merged anti serum and serum zones in the -flow 
cell and performing a two-point kinetic analysis- This was 
achieved by switching of-f the peristaltic pump 14 s after 
sample injection, measuring the turbidity 30 s and 60 s 
later and then re—activating the pump to flush out the 
reaction mixture. Complete automation of the FIA manifold 
and data collection and treatment were as described in 
Chapter 2-
Experiments were initially done in the antibody excess 
region only <0-1778 mg dl"1 IgG), and the results obtained 
for 5 replicate injections of each standard are shown in 
fable 3.8, and presented graphically in Figure 3.10. They 
indicate acceptable precision at the higher end of the 
range. Due to the long induction period required for the 
development of the immunoprecipitin reaction, however, 
sensitivity and reproducibility are poor at lower serum IgG
8 5
TABLE -3.8
Human Serum IgG Concentration versus Turbidity
using a Merging Zones FIA Manifold
Ail results are means of five replicates
Concentration Absorbance
Serum IgG_______SI ope  Standard Deviation___________RSD
(mg ol — x) (absorbance units min-1) (/!)
0 0 0 0
266 0 0 0
533 0.0053 0.00S 15.1
339 0.0147 0.0003 2.0
1155 0.0176 0.0012 6.8
1422 0.0233 0.0013 5.6
1773 0.0275 0.0013 2.5
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concentratians under the conditions used. This could be 
improved by increasing the stop time in the flow cell or by 
reducing serum and/or antiserum dilution, but this would 
lead to longer analysis times or higher reagent costs. Under 
the conditions described, the sampling rate was 
40 samples h -1 and the reagent cost was less than lp per 
analysis (i.e. less than i ul of undiluted antiserum per 
assay), which compares very favourably with 44p per analysis 
using RID (RID plate = 16 wells; price per plate = £7).
The between batch reproducibi1ity of the technique is 
shown in Figure 3.11. The error bars indicate the range for 
the pooled data, which consisted of of five results for each 
standard on the first run and five results for each standard 
on the second run one week later. Each point represents the 
mean of the 10 pooled results with a /CRSD < 4 7 . for values at 
the higher end of the range. The shape of the calibration 
curve is characteristic of immunoprecipitin reactions, with 
very slow reaction rates at low concentrations, rising 
through a linear region, to a plateau at the equivalence 
point. The curve shape was shown to be reproducible over 
several weeks and therefore a single—point calibration can 
be used when required, as is the case with commercial rate 
nephelometers . Antigen excess can be determined by 
dilution of suspect samples or by the use of single channel 
stop-flow FI A ‘17'> (Sect i on 3.2.5).
Another method for the detection of antigen excess is 
based on the difference in the shape of the rate curves,
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depending an whether the concentration of antigen is less 
than or greater than the kinetic equivalence point 
Since the fundamental primary reactions, and the ways that 
the primary products can interact to form larger aggregates, 
must differ under conditions of excess of the polyvalent 
antibody from conditions of excess of the divalent antigen, 
differences in the rate of increase of turbidity with time 
may be anticipated- As shown in Figure 3-12, the leading 
edges of the curves obtained for a particular sample are 
dependent upon whether or not antigen excess conditions 
apply- The above phenomenon is also observed when using 
stop—flow merging zones FIA, and could be exploited by the 
development of sophisticated software in order to 
distinguish between the two profiles, and thus confirm 
antibody/antigen excess conditions.
3.3.5 Quantitation of Serum Samples
Upon satisfactory completion of the above initial 
work the range of standards was increased to 0—3556 mg dl-1 
in order to accomodate the analysis of nine human serum 
samples (analysed by RID at Doncaster Royal Infirmary) and 
the U.S. National Reference Preparation. The analysed serum 
samples covered the range 500—3000 mg dl~1 and were diluted 
SOOX with PEG/NaCl prior to FIA analysis.
A set of results for the standards over the increased 
concentration range is presented in Table 3-9. Of interest 
is the location of the zone of equivalence at some 
concentration value greater than 2844 mg dl-1. As a
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TABLE 5.9
Human Seram IqG Concentration versus Turbidity using a
Merging Zones FIA Mani-fold — increased IqG concentration
All results are means o-f -five replicates
Concentrati on Absorbance
Serum IqG  Slope_______Standard Deviation RSD
(mg dl— 1) (absorbance units min-1) (7.)
0 0
0-0015 0.0006 0
711 0.0077 0.0009 11.7
1 4 : 0.0195 0.0004 2. 1
'133 0.0281 0.0006 !. 1
2844 0.0312 0.0009 2.9
3566 0.0244 0.0040 16.4
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consequence the interpolation of unknowns has been computed 
from a calibration curve in the range 0—2844 mg dl~x , i.e. 
the region of antibody excess. To allow interpolations of 
unknowns with concentrations greater than 3000 mg d l 1 would 
require an increase in working anti serum concentration so as 
to increase the range of the antibody excess region, or 
conversely further appropriate dilutions of the serum 
samples.
To allow interpolation of unknown values from a 
calibration curve, a first order linear least squares fit of 
the calibration data is usually computed. A linear fit of 
the data is commonly used since it is by far the easiest and 
quickest statistical analysis package to write. However, in 
this case a linear least squares fit would not yield a true 
representation of the data. This is due to the shape of the 
calibration curve, where at low concentrations an induction 
period is required for complex formation, and at the top of 
the concentration range the equivalence point is approached.
A second order curve fit of the data, as described by 
Ri tchi e <3:z> , was used in preference to a linear least 
squares fit. The results obtained by the FIA technique (FIA) 
are compared with the results obtained from RID in Table 
3.10, and the correlation between them can be described by 
the equation
(FIA) = 0.9841 (RID) + 29
with a correlation coefficient (r) of 0.9881, indicating the 
acceptability of the FIA method in yielding results
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TABLE 5-10
Flow Injection (FIA) and Radial Immunodiffusion (RID)
results -for ten Human Serum samples
FIA results are the means o-F two replicates
Sample Slope IqG cone./mg dl~x
(A.U. min-1) FIA RID
1 0.0141 877 930
2 0.0312 2693 2800
3 0.0096 643 650
4 0.0300 2402 2250
5 0.0106 689 500
6 0.0155 967 890
7 0.0195 1267 1230
8 0.0064 532 670
9 0.0170 1069 1170
10* 0.0180 1145 1128
* U.S. National Reference Preparation
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+ / -
-53
-107
-7
+ 152
+ 189
+77
+37
-138
-lOl
+ 17
comparable with those o-f the routinely used RID technique- A 
similar analysis to the above was carried out by using 
interpolated IgG concentrations -from a linear least squares 
■fit o-f the data, and the correlation between them may be 
described by the equation
(FIA) = 0.8832 (RID) + 392
with a correlation coefficient (r) of 0-9553, which shows 
much poorer agreement between the proposed FIA method and 
RID. The above information is presented graphically in 
Figure 3.13.
The result obtained by FIA for the U.S. National 
Reference Preparation (1145 mg dl— x) compares well with the 
quoted result (1128 mg dl— *) and seven separate 
determinations over a period of several weeks, using fresh 
standards each time, gave a between batch 71RSD of 9.871. This 
could be due in part to the long term instability of the 
reconstituted serum and within batch precision for sets of 
ten results ranged from 3.671 — 5.271. The quoted result for
the Reference Serum represents the mean of 232 analyses, 
carried out by 27 different col1aborators, on batches of a 
pooled human serum sample, using a variety of different 
analytical method5tAA> .
A typical recorder trace obtained for six standards 
(range 0—2844 mg dl-1) injected in duplicate, followed by 
five serum samples injected in duplicate is presented in 
Figure 3.14. From the trace it can be seen that the sample 
throughput is of the order of 40 samples h~x.
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5.3.6 Conclusions
The results show that the stop— flow merging zones FIA 
technique is suitable for the determination of human serum 
IgG using rate turbidimetric detection. The method provides 
a rapid quantitative result 90 s after sample injection and 
no sample pre—treatment, other than dilution, is required. 
The cost per assay is governed by the amount of antiserum 
used, and even allowing for wastage during the injection 
procedure, less than 1 ul of undiluted antiserum is consumed 
for each analysis.
By changing the serum and anti serum dilutions, and 
the type of antiserum the technique could be extended to the 
analysis of several other plasma proteins and certain 
therapeutic drugs.
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A. DEVELOPMENT OF ENZYME IMMUNOASSAY PROCEDURES 
USING FLOW INJECTION ANALYSIS
4 DEVELOPMENT OF ENZYME IMMUNOASSAY PROCEDURES USING
FLOW INJECTION ANALYSIS
4-1 Introduction
Substances o-f clinical or analytical interest, that 
are present at trace levels in biological -Fluids are now 
measured almost exclusively by immunoassay techniques*1’. 
The most widely used immunoassay methodologies use 
radio—labelling o-f one or more of the ligands, and can of-fer 
high sensitivity, with detection limits usually in the 
nanogram to picogram range when an energetic radionuclide is 
chosent2> . Employment o-f an energetic radionuclide prevents 
the use of radioimmunoassay in laboratories that are either 
unable, or unwilling, to manage the problems of safety and 
radioactive waste disposal. Furthermore, preparation of the 
labelled antigen/antibody involves health risks, and the 
protein shows batch—to—batch variation. Shelf— life is often 
limited to two months and may be even shorter if the 
radioactive decay causes destruction of the molecular 
structure(3>. The search for non—isotopic immunoassays with 
analytical performance similar to that of radioimmunoassay 
has led to the development of two systems based on enzyme*4 * 
and luminescent labels (both fluorescent*s> and 
chemiluminescent<<s> ) . Enzyme based immunoassays are at 
present the most widely used. This is due to their main 
potential advantage of signal amplification effected by the 
enzyme molecule acting on several substrate molecules. They
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also offer the advantage of a coloured end-point, that may 
easily be detected by spectroscopic means.
Fluorescent labels are inherently more sensitive than 
enzyme labels because of the greater sensitivity of the 
fluorescence process<a>. These assays, however, suffer from 
the background fluorescence of biological materials, 
together with the marginally higher cost of fluorescent 
instrumentation. The lack of suitable instrumentation has 
proved a problem with chemiluminescent assays. However, of 
these non—isotopic labels, only the enzyme—label can offer a 
visual end-point for rapid qualitative analysis or screening 
procedures.
result of advances in the fields of immunology, protein 
chemistry, and enzymology <'7'>. EIA techniques generally 
involve labelling an antibody or antigen with an enzyme such 
as peroxidase, and then measuring enzyme activity inhibition 
after an immunochemical reaction has occured. Improvements 
in protein isolation and purification, together with the 
availability of protein—coupling reagents, has aided the 
development of EIA. In 1960 Singer and Schick were the first 
investigators to succesfully couple two protein molecules 
without causing disruption of their biological and chemical 
activity.
glutaraldehyde was used by Avrameas<Q> in 1969 for the 
coupling of peroxidase to antibodies. Once this method
Enzyme—immunoassays (EIA) have become possible as a
Enzyme labelling proposition when
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became available, antibodies conjugated with enzymes were
used to locate and identi-fy specific tissue antigens by
light and electron microscopy <<?> . The use o-f enzyme-ant 1 gen 
and enzyme—antibody conjugates in heterogeneous immunassay 
svstems was -first reported in 1971 by Engvai i and
Ferlmann.*10’11’ and independently by van Weeman and
Schuurscl2> . The many applications and modi-fications of the 
EIA technique that have subsequently been reported 
demonstrate its potential -for clinical anaiy5i5<A> .
The following discussion focusses on non-competitive 
assays, as opposed to the more classical and commonly used 
competitive assays- The advantages of using a 
non-competitive assay protocol is that the number of steps 
in the analysis is reduced, the need for a large supply of 
standard antigen is removed (required as the competitor) and 
as a consequence EIA and automation procedures based on FIA 
would be greatly simplified.
Enzyme immunoassays are classified into two groups:-
1) Heterogeneous assays, in which the enzyme labelled 
antigen or antibody is separated from the enzyme labelled 
antigen-antibody complex before measurement of enzyme 
activity in either fraction. This procedure was termed 
enzyme— 1 inked immunosorbent assay (ELISA) by Engvai1 and 
Perlmann <10 >.
2) Homogeneous assays, in which the enzyme activity of 
labelled antigen is measured in the presence of labelled 
anti gen—anti body complex, the enzyme moiety of which is
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stericaiiy inhibited. This homogeneous EIA procedure was 
■first reported by Rubenstein<37> who used the technique to 
determine morphine,with a detection limit o-f 10“‘yM using 
lysozyme as the enzyme iabel. This method, termed the 
enzyme—muitipiied immunoassay technique (EMIT) has gained 
widespread use -for assaying hormones and drugs in body 
f i uids.
Both EMIT and ELISA are versatile methodologies 
designed to measure micro-amounts of substances in test 
samples. A comparison of EMIT and ELISA is given in 
Chapter 1.
4.1.1 EMIT : Basic Principles
The key elements in an EMIT reaction are the compound 
to be measured, enzyme labelled molecules of that compound, 
a specific antibody that binds the compound, and a specific 
chromogenic enzyme substrate. Two basic principles are 
involved in the EMIT assay:
1) the enzyme must retain activity after hapten, or 
anti gen/anti body conjuqation.
enzyme antigen * active enzyme-antigen -r
conjugate
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2) the enzyme activity o-f the hapten—enzyme conjugate must 
be reduced or increased when the hapten reacts with its 
speci-fic antibody.
active enzyme- anti^octy antibody bound enzyme
antigen conjugate antigen conjugate
(in-active enzyme)
A typical EMIT assay, e.g., Tor a therapeutic drug in 
a patient's bloodstream begins by adding to a patients 
specimen an excess of specific antibodies that will bind to 
the therapeutic drug being measured. If drug molecules are 
present they immediately bind to antibody sites. The 
enzyme—labelled antigen is then added to the mixture and 
antibody binding sites not occupied by molecules of the drug 
of the specimen are filled with molecules of the added 
enzyme—labelled antigen. Enzyme activity is therefore 
reduced because only free enzyme—labelled antigen can act on 
the substrate. The amount of substrate converted in a given 
period of time is determined by the amount of free enzyme 
left in the mixture. The sample analyte concentration is 
obtained by comparing the sample's rate of change of 
absorbance to that of a set of known standards. In this 
example, a high drug concentration in the patient sample 
causes many antibody sites to be occupied, leaving more
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enzyme— 1abel1ed antigen unbound and thus able to convert 
more substrate, resulting in higher absorbance readings. 
Inactivation of the enzyme label Nhen the enzyme-anti gen 
complex is antibody bound makes it possible -for the EMIT 
assay to be performed without separation of bound from 
unbound compounds, as is necessary with all other labelled 
immunoassy techniques. Thus, the EHII technique is most 
sensitive at high drug concentrations.
4.1.2. ELISA: Basic Principles
The technique of ELISA binds soluble antigens to solid 
phase antibodies or soluble antibodies to solid phase 
antigens in such a manner that both immunological and 
enzymatic activity is retained. Both a competitive and a 
double antibody "sandwich" ELISA technique are available for 
performing antigen/antibody determinations.
The "sandwich" technique is so called because the 
antigen to be measured is bound between two different 
antibodies, one of which contains the enzyme label. The 
steps in a double antibody "sandwich" ELISA assay for 
antigen measurement are depicted in Figure 4.1 . I n  this 
method, the inner surface of a polystyrene microtitre 
plate/tube is initially coated with antibody, specific for 
the antigen of interest, the antibody' being bound to the 
solid phase by physical or chemical means. After completion 
of this first seep, any unbound antibody is washed away. The 
sample, containing the antigen to be measured, is then added 
and the immunological reaction between the bound antibody
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and the sample antigen is allowed to proceed- Any unbound 
antigen is then washed away- A known amount of enzyme 
labelled antibody, produced in an animal species different 
•from that at the* bound antibody, in order to prevent the 
binding o-f the enzyme labelled antibody directly to the 
immobilized antibody,is allowed to react with the bound 
antigen. A different set of exposed antigenic determinants, 
which are not occupied by the solid phase antibody bond, are 
involved in this enzyme-conjugated antibody reaction. Any 
excess unbound enzyme-conjugated antibody is washed away. 
Unlike EMIT, bound enzyme conjugate remains enzymatically 
active in the ELISA system- When enzyme substrate solution 
is added, a colour change results, the absorbance of which 
is measured af.ter a fixed time period- The absorbance of the 
product is directly proportional to the concentration of 
standard/test antigen in the sample. Examples of the 
"sandwich" ELISA technique include methods for rat 
alphafetoprotein c13> and ^-aminotransferase'14’.
The type of competitive ELISA that utilises an 
antigen—enzyme conjugate is shown in Figure 4.2 - In this 
scheme, the first operation is the physical or chemical 
attachment of antibody to a solid phase. After washing away 
unattached antibody the solid phase bound antibody is 
incubated with a solution containing a fixed amount of 
enzyme—1abeiled antigen and either no unlabelled antigen 
(Figure 4.2a) or a known (but variable) concentration of 
standard antigen (Figure 4.2b) or an unknown concentration
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o-f test antigen from a sample (Figure 4.2b). These reaction
mixtures are then incubated until the antigen—anti body
reaction attains equilibrium. Fallowing a wash stage, the 
resulting bound antigen—antibody is incubated with the 
enzyme substrate solution. The absorbance of the product is 
then measured after a fixed period of time. The absorbance 
of the enzyme product is inversely proportion 
concentration of standard or test antigen in the initial 
sample. Examples of this competitive ELISA technique include 
the determination of rabbit IgG < and human chorionic 
gonadotrophin < .
4.1.3 Conjugation of Enzymes to Antibodies
The main objective in preparing an enzyme-labelled 
antigen or antibody is to obtain a stable conjugate with
high retention of both immunoreactivity and enzymatic
activity. The linkage of an enzyme to an antigen or antibody 
may affect the specificity of an assay if the chemical 
modification alters or masks key immunological determinants. 
Reviews on protei n~protein coupling075 and chemical 
cross-linking of proteins005 attest to the ease with which 
enzymes can be bound to antigens and antibodies, with some 
retention of immunological and enzymatic activity.
The coupling of proteins involves the use of a 
cross-linking reagent, which reacts via its active groups 
(at least two) with the functional groups present in enzymes, 
and proteins. Ihe cross-linking reagents reported are 
numerous and include cyanuric chloride095 , toluene
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diisocyanate<=so> , water soluble carbodiimides <=Bl * , and most 
importantly, glutaraldehyde<22'23>_ The functional groups 
found in the amino—acid side—chains of proteins include 
amino -NHa, imino ^NH, hydroxyl -OH, and thiol -SH.
Protein—protein coupling reactions have been classified € i7F> 
as either one—step or two-step processes. In a one step 
process<22>, the enzyme, the cross-1 inking reagent and the 
protein are all mixed together and allowed to react. In this 
process the reaction is difficult to control, mainly because 
the reaction rates of the functional groups in the enzyme 
and the protein are different. Additional problems with the 
one-step process include the selective polymerisation of 
either the enzyme or the protein. Furthermore, the
conjugates produced are basically heterogeneous i.e. the 
number of enzyme molecules conjugated to a protein molecule 
is variable. In the two-step process*23’ the enzyme is 
treated with an excess of the cross-linking reagent. After 
activation of the enzyme the excess cross-linking reagent is 
removed and the protein (antigen or antibody) is added.
Theoretically, in this two-step procedure the reaction is 
easier to control than in the one—step procedure. However, 
the success of this approach has been rather limited, since 
most enzymes are extensively cross-linked in the first step. 
During the two step procedure the enzyme is almost
exclusively activated first, mainly due to the fact that 
enzymes are cheaper than antibodies, and thus any resulting
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cross-1inking or polymerisation arising from this stage is 
not as costly as when the antibody is used.
From this account o-f currently available conjugation 
procedures it is clear that the coupling reactions, although 
chemically simple in principle, are very difficult to 
control in practice, so as to enable production o-f 1:1 or 
2:1 enzyme:anti body conjugates.
4.1.4 Automation o-f Enzyme immunoassay Procedures
Semi—automated £Mi i instrumentation consists of a 
spectrophotometer -for making absorbance measurements, a 
microprocessor tor timing and data-handlinq facilities and a 
semi-automatic pipettor—di1utor capable of delivering 
microvolumes of samples and reagents to the 
spectrophotometer.
ELISA systems have been developed for the screening of 
sera to aid the diagnosis of infectious diseases. Disposable 
polystyrene microtitre plates or cuvettes serve as antibody 
carriers and as liquid test reaction holders. ELISA tests 
performed manually can easily be read directly .in the same 
microtitre plate.
Continuous flow systems have been widely used in 
chemical analysis for the automation of wet chemical 
methods. In order to use continuous flow techniques to 
ancomahe c.ril I arcs tLi SA assay's, separation o+ pound and trss 
antigens must, if necessary, take pi ace on-nne. Continuous 
flew systems offer the advantage of well defined reaction 
conditions, such as time of contact between antigen and
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antibody, pH etc.. I-f a completely automated continuous -flow 
system could be designed -For immunoassay procedures it would 
necessarily fulfill the following requirements:
1) no/minimal manual interventions
2) versatile and applicable to a variety of assays
3) high precision of the assay
4) rapid
5) inexpensive
For ElA procedures, an attempt to fulfill these 
requirements has been made with the Southmead system<2A>. In 
this system the antibodies are coupled to agarose beads, and 
the immobilised antibodies are mixed with labelled antigen 
and serum sample, containing the antigen to be quantified, 
in an air— segmented stream. The mixture, consisting of 
agarose bound and unbound antigen fractions is directed to 
the separation block where separation of bound antigen from 
free antigen takes place continuously using a dialysis 
membrane. The stream containing unbound antigen (free as 
well as labelled) can then be used to quantitate the amount 
of free antigen in the sample by measuring its enzyme 
activity. However, the obvious disadvantages of this system 
are the continuous consumption of expensive immobilised 
antibody and enzyme conjugated antigen together with the 
need for an 'on-line' separation step which may not be very 
efficient.
Efforts to improve this system have made use of 
packed-bed reactors- A column packed with Sepharose—bound
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antibodies was adopted. The sample containing the antigen o-f 
interest is premixed with a known amount of enzyme—labelled 
antigen, and then introduced into the buffer flow. When the 
sample passes through the packed bed reactor competition 
between labelled and sample antigen for the available 
antigen—binding sites occurs. The time of contact is of the 
order of 1—2 minutes. On the application of substrate, the 
reaction that takes place in the column is due only to the 
enzymatic activity of the marker enzyme molecules bound to 
the immunosorbent. After the assay, the antigen—antibody 
complex is dissociated and the immunosorbent is ready for 
another assay. This approach has been applied to protein 
a n t i g e n a n d  hapten<ZA>assays. The advantages over 
conventional ELISA are :
1) the shorter time of one assay (8—15 minutes)
2) the antibody preparation is re—usable
3) on-line washing steps are introduced
4.1.5 Objectives of Automation of Enzyme Immunoassays
By using an automated FIA method it should be possible 
to make significant reductions in the consumption of 
expensive reagents, since FIA procedures require only 30 
or less of sample and reagent for each determination. Also, 
the final step of any ElA procedure is basically one of 
enzymatic activity determination, and FIA has already been 
shown to be a versatile analytical tool for enzymatic 
determinations, using both free*27’20’ and immobi 1 ised <2,r> 
enzymes.
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The systems studied here were all based on using the 
enzyme urease, as the immunolabel. This enzyme was chosen 
because urease is not present in the human body, and as such 
no endogenous activity should be observed when using real 
samples. The antigen to be determined during the course o-f 
this work is the one previously reported in Section 3.3, 
i.e., human immunoglobulin G. Thus, by employing various 
assay protocols it should be possible to quantify the 
enzymatic activity of the urease label in various 
environments, and relate the activity back to the amount of 
antigen present in the sample.
In order to study both EMIT and ELISA type assays 
using FIA, it was initially shown that the technique could 
be used to quantify the enzymatic activity of the urease 
label, both in the free form (for EMIT) and the immobilised 
form (for ELISA). By slight modifications to the FIA 
manifold it was then possible to study both EMIT and ELISA 
systems using human IgG as the antigen, urease labelled 
anti-IgG as the labelled antibody, and a pH indicator 
solution containing urea as the enzyme substrate.
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4.2 Determination of Urease Activity
4.2.1 Introducti on
The enzyme urease has been widely used -for the 
determination of urea concentrations in body fluids. 
Recently the use of urease (in free solution and 
immobilised) in FIA systems has been reported *30*31 9. A 
modification to the reported work is discussed here, since 
ElA procedures involve the measurement of the activity of 
the urease (label). The method of Ruzicka and Hansen ‘ 3 0 * for 
the determination of urea by FIA was based on the enzymatic 
formation of ammonia, its oxidation to chioramine, coupling 
with phenol and subsequent measurement of indophenol blue. 
By this method urea was determined in the range 2—20 mM and 
the measurement cycle for 1 sample was 25 seconds.
Another technique for the enzymatic determination of 
urea is based on pH measurements*32*339. The detector used 
was a flow-through capillary pH—electrode, and, by 
maintaining a constant buffering capacity of the carrier 
stream, a linear relationship between the recorded pH signal 
and the urea content was obtained. Urea was detected in the 
range 0-20 mM with a sampling rate of 60 samples hour-1. The
(a)
method of Ruzicka and Hansen, formed the basis of the work 
reported here, since a spectrophotometric detection system 
was used with the ElA procedures reported below.
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4.2.2 Experi mental
Reagents
The reagent .streams -for the indophenol blue (Berthelot 
method) consisted o-f:
a) urea 0.i mol I-1 (BDH>
b) 1 V. W V  sodium hypochlorite <BDH) 
c> phenol 0.1 mol I-1 (BDH)
Urease (urea amidohydrolase; E.C. 3.5.1.5) extracted 
from jack beans, was obtained from Sigma (U-2000, Lot
43F—7130). 130 mg of lyophilised powder was dissolved in
25 ml 10—* M phosphate buffer. This type of urease was
quoted as being equivalent to 39,900 u molar units g -i
solid, where 1 u molar unit is defined as liberating 1 u
mole of ammonia from urea per minute at pH=7 at 25c,C. Thus 
the stock solution prepared was equivalent to 207.5 u molar 
units ml-1.
Apparatus
The FIA apparatus used in the following experiments 
was as described in Chapter 2.
4.2.3 Continuous—Fiow FIA
In these studies a manifold similar to the one used oy 
Ruzicka and Hansen ‘3:3‘> was used (Fig 4.3). The manifold was
designed to allow for the sequential addition of reagents in
accordance with the reaction sequence in 4.2.1 .
The urea reagent stream <0.1 mol i ~A) was pumped at 
0.5 ml min~A through polypropylene tubing (0.5 mm id).
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Urease standards (30 u l ) were injected into the urea reagent 
stream using the automated PTFE rotary valve. The enzymatic 
degradation o-f urea to ammonia occurs in a polypropylene 
mixing coil i50 cm x 0.5 mm id). Downstream, sodium 
hypochlorite (i 7v/v; is added at a T piece to oxidize the 
ammonia produced to chi oramine. ft snort distance (5 cm) 
further downstream, phenol (0-1 mol i~A) is added for the 
coupling reaction and subsequent formation of indophenoi 
blue, the production of which is constantly monitored (62F 
nm> and the output fed to a chart recorder and an A/D 
converter. The absorbance value obtained was related to the 
activity of the enzyme.
Experiments were carried out using urease activity in 
the range 0—207.5 p. molar units ml-1. The results obtained 
for five replicate injections of each standard are shown in 
Table 4.1, and presented graphically in Figure 4.4 . Over 
this range a linear response was obtained with a correlation 
coefficient of 0.9946.
4.2.4 Cone1usi ons
The results obtained tor the determination of urease 
activity using FIA show that the final step of the proposed 
EMIT type assay is viable. A further consequence of the 
j'-esu its is inst rift c an d e  u . sad in ciinicai 1 ao or at or i es 
where monitoring of enzyme activity is of importance e.g. 
measurement of cardiac enzymes. In order to overcome 
problems with any low activity samples the FIA system could 
be operated m  the stop-f i ow mode.
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TABLE 4.1
Urease Activity versus Absorbance using a 
Continuous Flow FIA Manifold
All results are means o-f 5 replicates.
Urease Activity Absorbance
molar units ml~* Mean SD RSD
(absorbance units) (71)
0.0244 0.0009 3.7
21 0.0472 0.0030 6.4
52 0.0718 0.0020 2.9
104 0.0944 0.0026 2.8
156 0.1250 0.0028 2.3
208 0.1614 0.0031 1.9
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4.3 EMIT Procedures using FIA
4.3.1 Introduction
The aim o-f this work was to develop a -flow injection 
based automated homogeneous enzyme immunoassay -for the 
determination o-f serum IgG (antigen) . The enzymes most 
commonly used as labels in ElA procedures are horse radish 
peroxidase (HRP) and alkaline phosphatase (AP). These two 
enzymes have been -found satis-factory in many assays but have 
some disadvantages which limit their use. The major 
disadvantage of both HRP and AP is that they are present in 
many mammalian tissuesc33*, and as such give rise to large 
and variable background signals -for different samples. 
Urease (E.C 3.5.1.5) conjugates used with a pH indicator 
solution containing urea provide an ElA system which 
overcomes many of the problems encountered with HRP and 
A P <3‘*>. The colour change, on addition of a chromogenic 
substrate, is a sharp yellow to purple transition rather 
than the slow build-up of colour as seen with HRP and AP. 
The substrate is stable in aqueous solution at ambient 
temperatures and the enzymatic reaction may be stopped by 
the addition of a small quantity of an organomercury 
compound such as thiomersal <3S5> . Urease is not found in 
mammalian cells and hence no endogenous activity is observed 
when urease—antibody conjugates are used to detect 
cell-bound antigens.
Chandler et al <3-»> reported that the most suitable
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pH indicator -for the detection o-f urease activity was 
bromocresol purple- The substrate solution used in the EIA 
procedures reported here thus contained urea, bromocresol 
purple and EDTA, in quantities as speci-fieb in Section 4.3.2 
To date, there has been only one application o-f a coupled 
EIA by FIA r e p o r t e d . This paper described a homogeneous 
enzymatic -fluorescence immunoassay o-f serum IgG by 
continuous -flow FIA- The activity o-f the enzyme label, HRP, 
conjugated to the antibody (anti-human IgG) was inhibited 
upon immunochemical association- The inhibition o-f activity 
was monitored as a decrease in the laser induced 
fluorescence o-f dichlorof luorescein, produced by the 
HRP-catalysed oxidation o-f leuco-diacetyldichloro-
fluorescein by hydrogen peroxide- This procedure was 
performed at a rate o-f 60 samples hour-1 with a within run 
precision o-f 9-8/i- This paper was also the -first FIA example
o-f a non-competitive system -for antigen assay (c.f . Section 
4.1) and is similar to the method reported here- A major 
limitation with the m e t h o d i s  that the sample (antigen) 
is introduced into a continuously moving stream of the 
enzyme conjugated antibody, which is a very expensive 
reagent.. By using the merging zones techr.iqus(31> it should 
be possible to significantly reduce the amount of expensive 
reagent to 30 j j I per analysis. As a consequence, the 
merging—zones approach is used in the work reported here.
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4.3- 2 Experi mental 
Reaqgnts
An aqueous solution of sodium chloride <9 g I"'*) was
used for both the carrier streams in the FIA manifold and as
the serum/urease conjugated anti serum diluent.
Urease conjugated sheep anti—human IgS immunoglobulin 
(Sera Lab Ltd.) was used as the enzyme conjugated antibody. 
The original solution contained sodium azide <1 g I-1 , 
preservative) and 50 glycerol. Serial dilutions of the
conjugated antiserum were made in the range 1:40 to 1:140-
Human serum IgG standards were prepared by serial 
dilution (1:100 to 1:204800) of a human serum reference
material (Atlantic Antibodies), with a quoted value of
2638 mg dl — 1 IgG-
The substrate solution was prepared by the method of 
Chandler t37’> and was as follows: 8 mg bromocresol purple 
powder was dissolved in 1.5 ml 0.01 M NaOH and the volume 
made up to 100 ml with doubly-distilled water. After 
addition of 100 mg urea, EDTA was added to a final 
concentration of 0.2 mM to chelate any heavy metal ions 
which might inhibit the urease. The pH of the substrate was 
then adjusted to 4.8 using 0.01M MaGH or 0.1 M HC1.
Ail samples and reagents were stored at +4c*C when not 
i n use.
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Apparatus
The apparatus used for the following experiments was 
as described in Section 3-2,2 .
4.3,3 Static Experiments
These were performed in order to locate the zone of 
equivalence, to establish the optimum wavelength for 
(Tionitorinq the resultant reaction product, and to find a
sal cable reaction time for the flow-through method described 
below.
A wavelength scan over the range 700 nm — 370 nm for 
the substrate solution confirmed the presence of absorption 
maxima at 5S8 nm (purple, pH>5.2) and 430 nm (yellow,
pH<5.2), It was decided to work at 588 nm because at the 
optimum pH of 4,8 for the assay the absorption maximum was 
at 430 nm. Thus any increase in absorbance at 583 nm would
be solely due to the urease label converting the urea
substrate solution with a resultant increase in the pH of 
the solution and a shift in the X <*.«.>< to 583 nm.
In order to determine the optimum dilution of the 
human serum standards a i : 60 dilution of the
urease-conjugated antibody was chosen (Section 4.2.3 b.;.
Equal volumes (200 p.1 > of the ur ease-conjugated antibody and 
a range of dilutions of top standard antigen (1:1600 —
1:204800) were manually mi xea in tne micro-giass cuvettes, 
by inverting twice. After 60 s, 200 ul of tne substrate 
solution was added- and mixed by inverting twice, and a
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wavelength scan over the range 650 nm— 350 nm was obtained. 
The resultant data o-f absorbance at 588 nm versus serum 
dilution is presented in Tabie 4-2 . It shows that serum 
dilutions o-f approximately 1:70000 and more give rise to the 
condition of antibody (anti serum) excess and that a serum 
dilution of 1:51200 gives rise to the condition of antigen 
(serum) excess. 1 he data is presented graphically in Figure
4.5 and appears as an inversion of the classic 
immunoprecipitin curve (Fig 3-5). This is explained by the 
fact that inhibition of the enzyme label only occurs over a 
relatively narrow range of serum concentrations, at, or 
approaching the zone G f  equivalence. At the extremes of 
antigen and antibody excess little or no immunological 
reaction takes place, leaving the urease label free to 
convert substrate to product and thus a high absorbance 
value for the indicator solution is obtained. When the 
urease label activity is inhibited, at or near equivalence, 
a low absorbance value for the indicator is obtained. This 
pattern is clearly shown in Figure 4.5. Equal volumes of 
serum and urease con jugated anti serum were used in the above 
experiments to facilitate the transfer of the system to a 
merging zones FIA manifold.
Having determined a suitable dilution factor to ensure 
antibody excess (1:80000) a range of human IqG standards 
(0—2638 mg dl" *) were analysed by the above method. A 
typical set of results for the range of human IqG standards 
is tabulated in Table 4.3, and as expected shows, a decrease
127
TABLE 4.2
Serum IqG Dilution (2658 mg d l ~ M  versus Absorbance 
at 588 nm using a Static Spectrophotometer
All results are means o-f two replicates
Di1uti on p 1oqio di1uti on Absorbance
1:1600 3.2 0.1224
1:3200 3.5 0.1216
1:6400 3.8 0.0960
1:12800 4.1 0.0992
1:25600 4.4 0.0816
1:51200 4.7 0.0560
1:102400 5. 0 0.1152
1:204800 5.3 0.1320
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Table 4.3
Calibration PI at o-f IqG Standards versus Absorbanci 
at 589 nm using PE 5505 Spectrophotometer
All results are means of two replicates 
All serum dilutions X80000
Concentrati on Absorbance
mg dl~~* Iq G (A-U. at 588 nm)
0 0.220
396 0.217
791 0.196
1319 0. 192
16S8 0 . 165
2110 0.143
263S 0. 137
Correlation Coe-f-f i cient 0.9770
130
in indicator absorbance at 588 nm with an increase in serum 
IgG concentration- The correlation coe-f-f i cient -for the 
resultant calibration graph was 0-9770, indicating a 
non-linear response and the fact that the top standard was 
not within the antibody excess region- It is also clear from 
Figure 4.5 that complete inhibition of the urease label is 
not obtained, and that at best a 40% inhibition of the 
label's activity is observed. This could be due to a variety 
of reasons, one of which is that the pH detection system was 
very sensitive and slight mis—matching of the pH of the 
substrate with the serum and/or antiserum resulted in a high 
background.
4-3-4 Stop—Flow Merainq Zones FIA
The manifold used for the stop—flow FIA experiments is 
shown in Figure 4-6 . Teflon tubing CO-5 mm id) was used in 
these experiments in order to avoid problems of the 
enzyme—conjugated antibody adhering to the walls of the 
tubing (as the ELISA technique requires). The initial 
experiments involved the reproduction of the characteristic 
immunoprecipitin curve, as shown in Figure 4-5 by using a 
double stop—flow merging zones FIA procedure.
The two carrier streams were pumped at 0-5 ml min-1 
through Teflon tubing <0.5 mm id). A 1:60 dilution of the 
urease conjugated sheep anti—human IgG (30 ) and a range
of human serum standards <1:100 — 1:102400; 30 /il) were
simultaneously introduced into separate carrier streams 
using the automated PTFE rotary valve. Further downstream,
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the antiserum and serum zones were synchronously merged at a 
T—piece and passed into a teflon mixing column (6 cm x
1-5 mm id) , at which point the flow was stopped for 120 s. 
The flow was stopped in order for the immunological reaction 
to develop. The pump was then re—activated and the merged 
zones passed into a second T—piece, where the 
serum/antiserum zones were merged with a stream of the 
substrate solution pumped at 0-5 ml min~1 , and passed into 
the flow-through cell. The absorbance was constantly
monitored (588 nm) and the output fed to a chart recorder 
and an A/D converter.
The rate of the enzymatic reaction was determined by 
stopping a segment of the merged enzyme conjugated
antiserum/ serum/ substrate solution zones in the flow cell 
and performing a two—point kinetic analysis. This was 
achieved by switching off the peristaltic pump a second time 
148 s after injection, measuring the absorbance 30 s and 60 
s later and then re—activating the pump to flush out the 
reaction mixture. To ensure that no enzyme conjugated
antibody adhered to the teflon tubing/detector a 0.02M HN03
wash was introduced between samples. Complete automation of 
the FIA manifold and data collection and treatment were as 
described in Chapter 2.
The experiments were carried out with varying 
dilutions <1:100 — 1:102400) of the top serum IgG standard 
(2638 mg dl-1). The results obtained for two replicate
injections of each standard are shown in Table 4.4 and
1 3 3
TABLE 4.4
Absorbance versus Human Serum Standard (2658 mq dl~x) 
Dilution using a Stop—Flow Merging Zones Manifold
All results are means two replicates
Serum Dilution 1oq±odi1ution Slope 0 58B nm
(A.U. min-A)
Blank 0 0.0220
1: 100 0.0219
1: 200 2.3 0.0191
1:400 !. 6 0.0134
1:800 !. 9 0.0134
1:1600 3.2 0.0134
1:3200 3.5 0.0127
1:6400 3.3 0.0145
1:12800 4. 1 0.0134
1:25600 4.4 0.0152
1:51200 4.7 0.0165
1:102400 0 0.0176
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presented graphically as a plot o-f .logxodi lution (i.e.
logxodi lution) o-f human serum standard versus enzymatic 
reaction rate in Figure 4.7. Again, the inverted form of a 
conventional immunoprecipitin curve is clearly seen, with 
the antigen excess zone ranging from logxodilution values 
of 0—2.5 i.e. (Is 100 — 1:400 dilution) of the human serum
standard. The zone of equivalence, where the activity of the 
enzyme label is lowest, is clearly seen in the range of 
2.6—4.1 logiodilution values i.e. <1:400 — 1:12800
dilution). The antibody excess region of the curve, which is 
of importance for quantitative work, was observed at 
dilutions of the human serum standard greater than 1:12800. 
Thus, a dilution of greater than 1:20000 would ensure that 
the condition of antibody excess was met for all standards 
and samples in the range 0—2638 mg dl— x.
However, the system described above suffered from a 
lack of sensitivity, with differences in the rate 
measurements being restricted by the resolution of the A/D 
converter, i.e., 0.1 mv = 0.0007 a.u. min-1. Thus, as is
clear from Figure 4.7, the rate reading differences between 
a dilution of the top standard of 1:25600 and 1:51200 is 
very small. If a calibration curve for a range of IgG 
standards (0—2638 mg dl~x) were to be constructed, then the 
dilution factor of the serum would need to be fixed. Using 
this method it is clear that the sensitivity would be 
limiting, and as such no appreciable differences in
1 3 5
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enzymatic rate values would be obtained for the standards, 
and as such a calibration curve could not be constructed.
The limitations o-f the system are:
1) The enzymatic rate value for the blank, when no serum IgG 
is present, is relatively low. For this particular assay a 
high absorbance value is expected since no immunological 
reaction takes place and the enzyme label is 'free' to 
convert substrate to product. Thus a method is required 
whereby more "active" enzyme molecules are bound to the 
antibody so as to increase the initial signal.
2) Even at the zone of equivalence for both the stop—flow 
merging zones FIA and static methods, the activity of the 
enzyme label is only reduced by about 40%, which suggests 
that most of the enzyme molecules attached to the antibody 
are a large distance from the antigenic determinands on the 
antibody, and as such, upon immunological reaction their 
active sites are un-hindered, and free to convert substrate.
3) By using urease as the enzyme for labelling the antibody 
there is a need to use urea as the substrate molecule. For 
this purpose, urea is a relatively small molecule, and as 
such, the immunological reaction would need to proceed in 
such a way as to completely 'envelop' the urease label and 
prohibit the approach of the small substrate molecule. Thus, 
the immunological binding needs to proceed in a way that it 
may interfere with, or block entry to, the active site of 
the enzyme molecule. To meet the latter constraint it would 
be better to use an enzyme/substrate system where the
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substrate is a large, bulky molecule e.g. as in the system 
of Rubenstein<37,> who employed lysozyme as the enzyme label. 
The natural substrate -for this enzyme being the 
peptidoglycan of the cell walls of certain bacteria, with 
the bacteria being used as the substrate. With this system 
98 7. inhibition of enzyme activity was observed upon antigen 
binding.
4) The enzyme detection system employed, while being very 
sensitive to pH change, gave rise to problems if the pH of 
the carrier streams and samples/reagent were not at the 
optimum pH of 4.8, a system which would evidently not 
suffice if the pH of all serum samples were to be adjusted 
prior to subsequent analysis. Thus a detection technique 
based on some other method may be of more value, e.g. in the 
example reported a different technique for ammonia sensing. 
The Berthelot reaction for the formation of indophenol blue 
from liberated ammonia, while affording a method of 
measuring urease activity (Section 4.2.1), would not be a 
good choice for this method as the addition of various 
reagents in a step-wise manner would greatly complicate the 
manifold and the sequencing of events. Also the addition of 
reagents such as sodium hypochlorite and phenol may have a 
detrimental effect on the immunological reaction. It may, 
however , be possible to design a system whereby an 
ammonia—sensitive glass electrode is used as the 
detector t3e>.
1 3 8
4-3-5 Conclusions
Although this study o-f the EMIT system using the 
technique o-f FIA has not realised its promised potential, 
enough information has been obtained to show that the 
methodology is sound, but there may be a need to use a 
different system to obtain quantitative results- However, 
the work reported here shows that the EMIT type assay chosen 
here worked in a static system, in that the typical 
immunoprecipitin curve was obtained. It would be possible to 
overcome the sensitivity problems by using longer delay 
times so as to allow the reactions to develop. To do this as 
routine analysis would require more than one sample to be in 
the FIA system at any given moment.
The major problems are as previously discussed and 
thus the need for an enzyme/substrate system which employs a 
large substrate molecule, as well as the production of an 
active enzyme conjugated antibody needs to be emphasised. 
For future work on this topic, it is suggested that 
initially a different enzyme/substrate system is used, 
possibly the lysozyme/bacteria system which uses a 
turbidimetric finish— a method which has already been shown 
to be compatible with FIA methodology during this study 
(Chapter 3).
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4.4 Determinations using Immobilised Urease
4.4.1 Introduction
Enzymes have been applied to chemical analysis, 
particularly clinical analysis, since they are able to 
metabolize a given substrate with high efficiency and 
specificity. This feature is common in both free<27> and 
immobilised enzyme*29’ techniques. However, the use of 
immobilised enzymes is superior to that of free enzymes in 
the following respects*39’:
The lifetime of an immobilised enzyme is increased, i.e. 
immobilization stabilizes the enzyme.
The immobilised enzyme may be used for several assays
The immobilised enzyme is less sensitive to pH and
temperature change, of the surrounding medium.
The final step of an ELISA technique is an enzymatic 
activity determination of an immobilised enzyme. Thus, a FIA 
method for use in conjunction with immobilised enzymes would 
serve as a model for the work to be carried out on an ELISA 
type system.
The history of immobilisation of enzymes dates back to 
1916 when Nelson and Griffin first immobilised invertase on 
animal charcoal and alumina*39’.
There are four main immobilisation techniques:
1) Matrix Entrapped Immobilised Enzvmes*AO>
Enzymes can be immobilised within a cross-linked water 
insoluble polymer. This method has the advantage of being 
chemically simple and having wide applicability. The
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technique, however, has the limitations of poor -flow 
properties, low reactivity -for high molecular weight 
materials, slow leaching o-f the enzyme and inefficiency<AO> .
2) Immobilisation by Adsorption
This method has the advantage o-f being chemically very 
simple, widely applicable and having high initial yield. 
However, it has the limitation of requiring rigid control of 
conditions to prevent desorption.
3) Mi croencapsulati on
This type of immobilisation procedure has the 
advantage of high activity due to the high surface to volume 
ratio of the microcapsules, it is chemically simple and is 
flexible.
4) Covalent Attachment to an Insoluble Matrix
This type of immobilisation procedure was used 
exclusively in the work reported here, and is discussed 
below.
r
Immobilisation by covalent attachment means attaching the 
enzyme molecule to an insoluble matrix by at least one 
covalent bond. In order to preserve the activity of the 
immobilised enzyme, none of the amino—acid residues present 
in the active sites should be involved in the bonding. It is 
also important that the conditions used for the coupling 
reaction are very mild, so as not to cause denaturation of 
the enzyme. For this reason, temperature and pH should be 
carefully controlled.
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a) Solid Supports
Many solid supports have been used as a matrix -for 
enzyme immobilisation by covalent bonding including
polystyrene, which was used during the course o-f this study, 
and controlled pore glass.
b) Activation of the Solid Support
In order tor the solid support to be suitable for 
covalent attachment of the enzyme molecule, it is necessary 
to introduce or liberate a functional group which will 
undergo a coupling reaction with the enzyme molecule under 
mild conditions. One example of introducing a functional 
group to a carrier is si lanization ,e. g. the activation 
of glass beads with 4—aminopropyltriethoxysilane.
c) Cross-1i nki nq
By far the most popular reagent for cross-linking the 
enzyme molecule with the activated carrier, is 
glutaraldehyde. The way in which it is employed in the 
immobilization sequence is shown in Figure 4.9.
The immobilisation of enzymes by covalent linkage has 
the advantage of being a very flexible approach; yielding a 
system with good flow properties and very little/ no 
desorption of the enzyme.
FIA experiments were carried out using urease 
immobilised on polystyrene and controlled pore glass, in 
order to assess the feasibility of using the technique in 
conjunction with an ELISA type system.
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4-4.2 Experi mental 
Reagents
i) Immobilisation Procedures 
Polystyrene beads (20/50 mesh), (Sigma).
Controlled pore glass (CFG) (120/200 mesh), (Sigma). 
The urease used was as described in Section 4.2.2. 
i i ) Flow Injection Analysis
The carrier stream consisted o-f doubly distilled water 
adjusted to pH 4.8 prior to use with 0.01M NaOH /
0.01M HC1.
The pH indicator stream consisted of bromocresol 
purple (40 mg l-1) adjusted to pH 4.8 as above.
Apparatus
The FIA apparatus used in the following experiments 
was as described in Chapter 2.
4.4.3 Immobilisation Procedures
a) Immobilisation of Urease on Polystyrene 
The reaction sequence for this procedure is shown in 
Figure 4.8.
Method
Polystyrene beads (20/50 mesh, 3g), previously swollen 
in chloroform (2 hours), were added slowly to stirred, 
ice-cold, fuming nitric acid (40 ml). The mixture was then 
refluxed for four hours on a heating mantle. The beads were
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R e a c t i o n  Scheme
CH—  CH -
1) fuming HNO^
 CH— CH -
NO.
2) Sn/HCl
V
 CH — CH,
| 3) NaN02/HCl
 CH — CH2---
r S
N— N
4) HO
V
 CH— CH2---
Diazonium salts react with
lysyl, tyrosyl and histidyl
,—  . amino acid residues.
N— N-/ ^-Urease
then poured into cold water and washed until acid -free 
(1itmus).
To the resulting nitropolystyrene beads, stannous 
chloride (25g), conc. HC1 (50 ml) and ethanol (20 ml) were 
added. The mixture was then re-fluxed -for twenty -four hours 
to yield brown beads. The beads were then filtered and 
washed with water and 2M NaOH in order to release the free 
aminopolystyrene.
Aminopolystyrene (200 mg) was weighed into a 50 ml 
volumetric flask and shaken with 2M HC1 (20 ml) and 27. 
sodium nitrite (8 ml) in ice for 15 minutes. The solution 
was decanted off and the beads washed three times with ice 
cold phosphate buffer (pH 7).
Urease (0.3 g) in ice cold phosphate buffer (25 ml) 
was added to the reddish coloured beads and the resulting 
mixture gently shaken overnight at ^ C .  The immobilised 
enzyme was washed with ice cold buffer and stored in the 
buffer at 40C until required.
As a check on the above procedure an infra-red 
spectrum of the beads was taken after each stage (KBr disk).
b) Immobilisation of Urease on Controlled Pore Glass 
Two procedures for immobilising urease onto CPG are 
discussed here, since they link to different amino acid 
residues on the enzyme. In the case of glutaraldehyde 
coupling, the bonding is through the lysine amino acid 
residue, whereas with the diazotisation procedure bonding is 
through the tyrosine or histidine amino acid residues.
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Reaction Scheme
Controlled Pore Glass (CPG)
1 ) 4-aminopropyltriethoxysilane
V
CPG —  Si —  (CH2)3  NH2
2) glutaraldehyde
'C
o
P
3
CD
s:
CD
d
rH
cC
U
cfl
P
d
pH
o
I 0I I
CPG — Si —  (CH2)5 - N =  CH - (CH2)5-  C -  H
3) urease —  NHf
CPG - Si - (CH2)3 - N = C H  - (CH2)3 - CH =  N
I 46
- Urease
i) Glutaraldehyde Procedure
The reaction sequence -for this procedure is 
shown in Figure 4-9.
Method
Controlled pore glass (lg) was mixed with 10 ml dry 
toluene containing 10 '/.w/w 4-ami nopropyl t r i ethoxy si 1 ane and 
the resulting mixture re-fluxed -for twenty -four hours in an
oil—bath- The silylated glass was washed with toluene and
acetone using a grade 4 sinter Buchner -funnel- The resulting
o-f-f—white particles were left in the sinter, covered by
filter paper and left in a dessicator to dry overnight.
The particles were then magnetically stirred with 
20 ml glutaraldehyde (12-5 Xw/V) in 0 . 1M sodium borate 
buffer (pH = 8-5) at 0°C for one hour- The resulting orange 
product was washed with buffer and immeadiately used in the 
preparation of immobilised urease.
The particles were then stirred with 10 ml of urease 
solution (0.3g urease dissolved in 25 ml phosphate buffer) 
for four hours at 0°C.
The dark red particles produced by the latter were 
washed and stored in buffer at 4c*C until required.
i i ) Diazotisation Procedure
The reaction sequence for this procedure is shown in 
Figure 4.10
Method
Silylated particles (200 mg) obtained from (i) above 
were used for this procedure. The particles were refluxed
U 7
Reaction Scheme
Controlled Pore Glass (CPG)
1) 4-aminopropyltrietlioxysilane
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CPG -  Si -  (CH2)3 -  NH,
2) p-nitrobenzoylchloride
T 0
I i!
CPG -  Si -  (CH2)3 -  NH -  C ) NO,
3) sodium dithionite (aq)
0
CPG -  Si -  (CH0)- -  NH 
I
k) HC1 / NaNO,
-s-O NH,
0
CPG -  Si -  (CH2) ^  —  NH —  C N-N
5) urease
O
OH
CPG -  Si -  (CHn)„ -  NH
i 2' y
r \ N-N urease
1^8
-for twenty -four hours in 10 ml chloroform containing 10 %w/w 
p—ni trobenzoyl chloride and 10 7£w/w triethylamine. The
resulting acylated particles were washed in chloroform and 
dried as before- The aryl nitro group was then reduced by 
refluxing for two hours in 10 ml aqueous 8 7Cw/w sodium 
dithionite. The resulting pale yellow particles were washed 
thoroughly with acetone.
The powdered glass was diazotised by shaking with 2M
HC1 (20 ml) containing sodium nitrite (1 g) at 0°C for four
hours- The product was then washed with IV. w/w sulphamic 
acid (aq) to remove traces of NaN02 .
To couple the enzyme, the glass beads (200 mg) were 
immediately slurried in 25 ml phosphate buffer (pH 7-5) , 
containing urease (0-3 g) and gently shaken for four hours 
at room temperature.
The dark orange powdered glass was thoroughly washed
and stored in phosphate buffer at 4°C until required.
The above schemes are also applicable to the 
immobilisation of antibodies enzyme conjugated antibodies.
4-4.4 Continuous Flow FIA
For these studies the FIA manifold was as depicted in 
Figure 4-11- The doubly distilled water carrier stream was 
pumped at 0.5 ml min-1 through polypropylene tubing (0-5 mm 
id). Urea standards (30 u l ) were injected into the carrier 
stream using the automated PTFE rotary valve. A short 
distance downstream (5 cm) there was a second PTFE rotary 
valve which contained two sample loops, one of which
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contained the immobilised urease column, and the other 
contained a dummy column (i.e. an inert glass bead column). 
It was necessary to operate the system in this configuration 
so as to allow individual blanking o-f all the standards.
Thus, the second valve may be in one o-f two positions, and
as a consequence the urea standard may either pass through 
the immobilised urease column or through the dummy column. 
This individual blanking technique was used in order 
overcome problems associated with any pH mis—matching o-f 
standards and carrier stream. This blanking technique is
important since the analytical read—out is given by a pH
sensitive indicator.
As the urea sample slug passes through the immobilised 
urease column, enzymatic degradation of urea to ammonia 
occurs, thus increasing the pH of the solution. This pH 
increase is detected by the pH indicator stream which merges 
with the main stream a short distance <2 cm) after the
column. The increase in pH is monitored at 588 nm and the 
output fed to an A/D converter and a chart recorder. If the 
sample is allowed to pass through the dummy column, the 
native pH of the sample is obtained and used for any 
subsequent calculations.
Experiments were carried out using the immobilised 
urease on polystyrene preparation with urea standards in the 
range 0-250 mg l-1. The results obtained for five replicate 
injections of each standard are shown in Table 4.5, and 
presented graphically in Figure 4.12. Over this range a
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TABLE 4.5
Urea Concentration versus Absorbance using Immobilized 
Urease in a Continuous Flow FIA Mani-fold
Ail results are means o-f -five replicates.
Concentration Absorbance
Urea / ppm Mean 5D R5D
(absorbance units) (X)
0 0 0 0
50 0.0072 0.0005 7.5
100 0- 0133 0.0004 3.2
150 O .0238 0.0010 4.0
200 0-0327 0.0024 2.1
250 0.0396 0.0020 4.9
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linear response was recorded with a correlation coefficient 
o-f 0-9972. Similar results to those presented here were 
obtained -for the other immobilised urease preparations, as 
described previously in Section 4-4-3.
4-4-5 Conclusions
The results obtained with this FIA mani-fold clearly 
show that the technique readily avails itsel-f to studies 
involving the use o-f immobilised enzymes- The advantages o-f 
using immobilised enzymes as compared with free enzymes are 
that immobilised enzymes are re-usable for many analyses and 
that the preparation is stable foe many months. Thus, from 
these preliminary studies it appears that the final step of 
an ELISA type procedure is within the scope of this FIA 
technique-
4.5 ELISA Procedures using FIA
4-5.1 Introduction
The work described here is a modi-fication o-f the ELISA 
technique described previously (Section 4.1), in that the 
antibody enzyme conjugate is immobilised onto polystyrene. 
The conjugate preparation is very expensive, and thus a 
method of re-cycling it Mould clearly be beneficial. By 
using this approach it should be possible to monitor the 
activity of the conjugated enzyme in a similar fashion to 
the work described in Section 4.4. The assay is based on 
measuring the decrease in activity of the immobilised 
antibody conjugated enzyme label as a consequence of 
antibody—antigen (sample) binding. Thus, when no sample 
antigen is present a signal due to the immobilised 
conjugated enzyme is observed. However, upon addition of 
sample (antigen), an antibody—antigen reaction will occur 
and the activity of the enzyme label will decrease due to 
steric hinderance of the enzyme's active site. This decrease 
in activity can subsequently be monitored and used to 
quantify the amount of antigen present. The immobilised 
conjugated antibody—enzyme column can then be regenerated by 
the addition of a conformation changing medium e.g. 4—6 M 
urea or 2-4 M NaSCN<^3>.
Thus, by using the proposed method and applying it to 
FIA all the washing steps employed in the classical ELISA 
method are achieved on-line. Also, by immobilising the 
antibody-enzyme conjugate there is no need for a second
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antibody as there is in the 'sandwich' ELISA technique. A 
consequence o-f these modifications to the classic ELISA 
technique is that the assay protocol is greatly simplified 
arid that the expensive antibody—enzyme conjugate is 
re-cycled.
The reagents used here are as described in Section
4.1.5 and include the use of urease conjugated goat
anti—human IgG immobilised on polystyrene for the detection 
of human IgG (antigen).
4.5.2 Experimental 
Reagents
The carrier stream consisted of doubly distilled water 
of pH 4.8 (adjusted with 0.01 M NaOH / 0.01 M HC1).
The pH indicator stream consisted of bromocresol 
purple (40 mg 1— 1) adjusted to pH 4.8 as above.
Human serum IgG standards were prepared by serial 
dilution (1:100 — 1:51200) of a human reference material
(Atlantic Antibodies), with a quoted value of 2638 mg dl— 1
For these studies the enzyme—antibody conjugate was
formed after initial immobilisation of either the enzyme or
antibody to the polystyrene solid support. This procedure 
was adopted so that it would be possible to study two 
similar systems simultaneously i.e. systems whereby an 
antibody—enzyme conjugate was immobilised onto polystyrene:
a) through the enzyme molecule Polystyrene—E—Ab
b) through the antibody molecule Polystyrene—Ab—E
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The -first stage of this procedure used the diazonium 
coupling reaction described above in Section 4.4.3. The 
second stage of the procedure used glutaraldehyde to couple 
the two proteins via their lysine amino acid residues. Using 
the diazonium procedure in the first step ensured that no 
active sites on the polystyrene solid phase were left for 
attachment of the second protein, since the diazonium salt 
produced 'in—situ' is very unstable.
The second stage of the procedure was carried out in a 
flowing stream, with the previously immobilised 
enzyme/antibody held in a 4 cm x 1.5 mm id Teflon tube. A 
peristaltic pump continuously pumped the activating reagent, 
1 7.w/V glutaraldehyde through the column for 18 hours at 
room temperature. The excess glutaraldehyde was then washed 
off the column using pH 7 buffer, pumped for 4 hours at room 
temperature in a closed loop type system. A second protein 
was then pumped through the column for 24 hours at room 
temperature and any excess washed off as described above. 
For this second step the concentration of urease was 12 mg 
ml-1 (39,900 u molar units g— 1), and the concentration of 
the antibody solution was a four— fold dilution of the 
supplied preparation. When not in use the columns were 
stored in pH 7 phosphate buffer at 4 *=*C, and flushed through 
with pH 4.8 doubly distilled water immediately before use.
Another procedure adopted in order to further simplify 
the immobilisation steps was to co—immobi1ise the urease and 
the antibody onto the polystyrene solid support by the
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diasotisation method- This procedure was used to de—activate 
enzyme molecules on neighbouring sites to the antibody 
molecule by addition o-f sample antigen. The procedure 
adopted used 100 mg polystyrene taken -from the diazotisation 
step as described in Section 4-4-3- To these beads were 
added a 1 ml aqueous solution o-f 10 mg urease and 30 mg goat 
anti—human IgG, which was gently stirred overnight at room 
temperature.
Urea standards were prepared in the range 0— 1000 mg 
dl_1 and adjusted to pH 4-8 prior to use.
Apparatus
The FIA apparatus used in the -following experiments 
was as described in Chapter 2-
4-5-3 FIA Procedures
For these studies the FIA manifold was as depicted in 
Figure 4-11- The column containing the immobilised 
antibody—enzyme conjugate was placed as the injection loop 
of the second valve and a dummy column was also used for 
reasons discussed above Section 4-4-4-
The ELISA type systems studied here are discussed in 
order of the type of antibody—enzyme conjugate column used 
as follows:
a) Polystyrene — Enzyme — Antibody column (P—E—Ab)
b) Polystyrene — Antibody — Enzyme column (P—Ab—E)
c) Co—immobilised Antibody/Enzyme column.
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The protocol adopted -for these assays was as 
previously described in Section 4.5.1, with the actual 
enzymatic activity determination being carried out as in 
Section 4.4.4.
4.5.3 a) Polystyrene — Enzyme — Antibody
The P-E—Ab column used in these studies was derived 
■from the polystyrene — urease column used in previous 
studies reported in Section 4.4.4. The further conjugation 
of the antibody onto the column was achieved by the 
glutaraldehyde method described in Section 4.5.2. Results 
presented in Section 4.4.4 show abundant enzyme activity 
with a signal of 0.04 A.U. obtained with a 30 i^l injection 
of a 200 mg 1— 1 urea standard. However, upon further 
conjugating the polystyrene — urease column with the 
antibody to form the P—E—Ab column, no enzyme activity was 
observed even when using a 10000 mg 1“ x urea standard. The 
loss of enzyme activity was probably due to the blocking of 
the enzyme active site by the incoming antibody molecules.
The problem with this arrangement is that it is 
difficult to control the number of antibody molecules 
attached to a single enzyme molecule in the second step of 
the, conjugation procedure. The glutaraldehyde used activates 
the lysine amino acid residues on the immobilised urease 
prior to conjugation of the antibody. However, there may be 
a number of lysine residues available for activation and, as 
such, more than one antibody molecule may become attached to 
a single enzyme molecule, thus rendering it inactive- Any
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•future experiments using the P—E—Ab system would therefore 
need closer control of the second conjugating step so as to 
produce a 1:1 relationship between the bound enzyme and the 
incoming antibody- This may be achieved by studying the 
concentration and reaction time required for the 
glutaraldehyde activation step. By producing a 1:1 or 1:2 
enzyme:antibody conjugate it should be possible to preserve 
some of the enzyme activity on the column.
4.5.3 b) Polystyrene — Antibody — Enzyme
The P—Ab—E column used in these studies was obtained 
by immobilising the antibody onto the polystyrene solid 
support using the diazotisation procedure described in 
Section 4.4.3. Conjugation of the enzyme onto this column 
was achieved via the glutaraldehyde cross-linking method 
described in Section 4.5.2.
When using this type of column no enzyme activity was 
observed when using 30 u^l injections of urea in the range 
0-1000 mg 1— 1. However, upon increasing the concentration to 
2000 mg 1~1 a signal of 0.03 A.U. was generated for a 30 ul 
injection. For ELISA type systems, this would represent the 
blank value and with any antigen present in the sample this 
value should decrease.
However, upon passing 30 ul injections of a wide range 
of antigen solutions <1;51200 — 1:800) over this column, in 
both the continuous flow and stop—flow mode, no reduction in 
the 0.03 A.U. signal was observed. The stop—flow made 
involved stopping the flow when the sample (antigen) zone
160
was on the column. During the course of this study the 
stop—time was varied from 3 minutes to 18 hours, with no 
decrease in the enzymatic activity observed for any 
stop-flow time.
The problems associated with this column are similar 
to those discussed previously for the P-E—Ab column, 
although this could not account for the relatively low 
enzyme activity on the column (i.e., requiring a 2000 mg 1“ 1 
urea solution to produce a signal). This in turn indicates 
that the diazotisation procedure used to immobilise the 
antibody to the polystyrene solid phase is not very 
efficient. This derives from the fact that the second 
coupling reaction (enzyme onto immobilsed antibody) is 
difficult to control, and as such numerous enzyme molecules 
may be attached to one immobilised antibody molecule. Thus, 
if the immobilising procedure for the antibody was 
efficient, a large enzyme activity should have been 
observed.
Also, by using the P—Ab—E configuration, problems of 
accessibility of the antibody binding site to the sample 
antigen may be anticipated. Since the coupling of the enzyme 
to the immobilised antibody is difficult to control, many 
enzyme molecules may be bound to a single antibody molecule. 
This situation would lead to exclusion of the antigen from 
the antibody binding site.
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4-5.3 c) Co—immobi1ised Antibody/Enzyme
The co—immobi1ised antibody/enzyme column used here 
was prepared by the method described in Section 4-5-2- By 
using this technique it may be possible to decrease the 
enzyme activity on the column by -forming anti body-anti gen 
complexes on neighbouring immobilised antibody sites.
As expected, a relatively large enzyme activity was 
initially observed on the column with a signal of 0-08 A.U. 
observed with a 30 jul injection of 50 mg 1— 1 urea- Upon 
addition of the antigen solutions in a similar manner to 
Section 4-5-3 b) no reduction in this initial signal was 
observed-
On this occasion the problems could be confined to the 
fact that immobilized antibody—antigen complex formation has 
no effect upon the enzyme activity of enzyme molecules 
immobilised on adjacent sides. Also, as discussed in Section 
4-5-3 b) the diazotisation procedure is inefficient for 
immobilising the antibody onto the solid support- As a 
consequence, the activated sites on the polystyrene solid 
phase may have been saturated with enzyme molecules, thus in 
effect producing an immobilised urease column- If this was 
the case, then, as observed, addition of antigen to the 
system would have no effect upon the enzyme activity-
4-5.4 Conclusions
The non-competitive ELISA type procedures described 
here did not realise their potential in that no human serum
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samples were analysed. By using a non-competitive type assay 
the FIA mani-fold is simplified and the amount of reagents 
required is reduced. When using a competitive type system 
there is a requirement for an enzyme conjugated antibody
together with standard antigen for each assay.
From the work described here it is clear that 
measurement of enzyme activity, with the enzyme immobilised 
onto a solid support, is possible using FIA. This
measurement represents the final step in any ELISA
procedure. From the work described here it may be possible 
to further exploit the P—Ab-E column. For this a choice of a 
more suitable solid phase and immobilizing procedure for 
obtaining a higher concentration of antibody on the solid 
support would be advantageous. As such, different solid 
supports coupled with appropriate immobilising procedures 
need to be investigated and the amount of antibody 
quantified. This work would be invaluable in allowing the 
correct choice of solid support/immobi1isingh procedure to 
be made, so as to ensure the maximum amount of antibody 
immobilised on the column. Control of the second conjugating 
step must also be achieved in order to produce 1:1 
(antibody:enzyme) columns.
During the course of this study it has been shown that 
the technique of FIA would be useful for clinical analysis, 
particularly in small laboratories where the speed, 
flexibility and cheapness of the system would be 
advantageous. The technique has been shown to be good for
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turbidimetric methods and also -for measurement of enzyme 
activities, both in -free solution and immobilised states. It 
is also clear -from this work that a greater understanding o-f 
the enzyme - antibody/antigen interactions is needed before 
further developments in the field of enzyme immunoassays 
using FIA is possible.
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5. QUALITATIVE FLOW INJECTION ANALYSIS APPLIED 
TO ABO BLOOD GROUP DETERMINATIONS
5 QUALITATIVE FLOW INJECTION ANALYSIS APPLIED TO
BLOOD GROUPING
5.1 Introduction
Blood groups are systems o-f antigens and 
antibodies which have genetic, biochemical and immunological 
implications- Blood group antigens, which are under genetic 
control, are -found on the red cell surface, while their 
corresponding antibodies exist in the immunoglobulin 
■fraction o-f the plasma, though not in the same person41 >« 
In Landsteiner's original experiment<2>, which led to the 
discovery o-f the ABO system, the - serum of a number of 
individuals was tested against their own red cells and the 
red cells of all the others in the group. Three different 
patterns of reaction were obtained, two being more common 
than the third- The results of the experiment made it 
possible to divide the population into three groups, which 
he called A, B and 0- One year later the existence of a 
fourth, less common group, AB, was established<3>. This 
experiment marked the beginning of the discipline of blood 
group serology and made blood transfusions practicable.
The four groups are determined by the presence 
or absence on the red blood cells of the blood group 
antigens A and B, and therefore, the blood group of the 
individual is either A, B, AB, or 0 (0 denoting the absence 
of A and B) . In addition it has also been shown that 
corresponding to the antigens A and B there are antibodies 
anti—A and anti—B, which occur as agglutinins in the serum
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o-f individuals whose red cells lack the corresponding 
agglutinogen (antigen). The agglutinogen and agglutinin 
content o-f the red cells and serum of the four blood groups 
are shown in Table 5.1.
TABLE 5.1
Agglutinogen and Aaalutinin content of the Red Cells 
and Serum of the Four Blood Groups
BLOOD GROUP Agglutinogen (antigen) Agglutinin (antibody)
on red cells in serum
A A Anti—B
B B Anti—A
AB A and B Neither
0 Neither Anti—A and Anti—B
The ABO grouping of individuals is carried out by 
means of agglutination reactions using anti—A (prepared from 
serum of group B) and anti—B (prepared from serum of group 
A ) , or by the use of mouse hybridoma monoclonal antibodies. 
Agglutination is by far the most important and widely 
observed phenomenon in blood grouping. The agglutination of 
red cells takes place in two stages. In the first stage the 
serum agglutinins (antibodies) become attached to
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agglutinogens (antigens) on the red cell surface. A red cell 
which has thus taken up agglutinins is said to be 
sensitised. In the second stage the actual agglutination or 
clumping o-f the sensitised red cells takes place. The cells 
-form aggregates which, if large enough, are visible to the 
naked e y e <4>. Thus in blood grouping, clumping or 
agglutination of red cells is the observable result of 
mixing cells containing a particular antigen with a serum 
containing the corresponding antibody. The pattern of 
reactions obtained for each blood group, by the above method 
is shown in Table 5.2.
TABLE 5.2
ABQ Grouping, using Standard Sera and Standard Red
Cells
BLDQD GROUP REACTIONS OF RED CELLS WITH SERA
Anti —A____________Anti—B
A C
B _ C
AB C C
0
Key C = Complete agglutination 
— = No visible reaction
170
The subject o-f human blood groups is a complex one 
and as such there are available a number of techniques -for 
blood group typing. Common to all, however, the chief 
manipulation in a blood grouping laboratory is the mixing 
together of small quantities of red cells and serum and the 
subsequent observation as to whether or not the red cells 
nave been agglutinated by an antibody in the serum. The 
mixing is effected most accurately and conveniently by 
delivering small volumes of red cell samples and sera with a 
graduated Pasteur pipette into precipitin tubes or onto 
ceramic tiles (the latter of which is very rare nowadays).
More recently however, blood grouping has been done 
using a multi-channel modification of an air segmented 
continuous flow analyser<s>. The instrument is relatively 
simple; serum and test cells are mixed together and pass 
through coiled plastic tubing, the reagents are thus 
continuously and gently mixed for a period of about 10 
minutes. The sample then passes on and is diluted with 
saline, the agglutinates formed (in the case of a positive 
sample) settle as the sample approaches a decant 'T' piece 
where the agglutinates and a portion of unagglutinated cells 
are decanted from the system while the supernatant travels 
on. Further downstream the cells in the supernatant are then 
lysed (breaking up of the cell wall followed by release of 
haemoglobin) and the degree of lysis is measured 
spectrophotometrically. A low reading indicates that most of
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the cells have been removed as agglutinates (at the decant 
'T' piece) and thus denotes a positive reaction.
Also, automatic blood group analysers have become 
avai lable <<s> . One in particular is designed specifically to 
meet the needs o-f blood donor centres and hospital blood 
banks. It is capable o-f processing and printing results -for 
samples simultaneously at a rate o-f 80 samples hour-1. In 
this method samples are placed in tubes on a carousel and 
processed in batches o-f 12. The red blood cells are 
automatically diluted with saline solution and incubated tor 
10 minutes. After this period samples and reagents are 
loaded into a reaction disc holding 144 cuvettes. Each 
reaction is processed in a separate cuvette and each sample 
is processed in a separate 12 cuvette sector (i.e. there are 
twelve separate tests carried out per sample, including ABO 
and Rhesus typing). The disc is then incubated at room 
temperature for 2 minutes, spun for 1 minute and finally 
agitated at four different speeds in order to bring possible 
agglutinates to the centre of the cuvette. The disc is then 
read by a photometric unit while the identification number 
of the sample is read simultaneously.
The major disadvantages of the processes described 
above are the high capital cost of the instruments e.g. 
£40K-100K and the need for large sample batches to make them 
commercially viable.
By using FIA instead of the above instruments it is 
possible to reduce the consumption of expensive reagents (to
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typically 30 ul per sample) by operating in the 
merging—zones mode. There is also the possibility of 
on-line dilution o-f the sample and subsequent stream 
splitting -for the introduction of antisera prior to 
analysis <‘7'> . The aim of this study was to show that FIA 
could offer a suitable low-cost alternative to existing
techniques for ABO blood grouping in clinical and forensic
laboratories handling small (or one-off) sample batches.
This work on ABO blood group typing is a rare (if 
not the first) example of a qualitative FIA technique. To 
date, there have only been examples of quantitative FIA 
techniques reported in the literature. Thus, this report 
further enhances the claim that FIA is a very versatile 
technique, and as such may be used for both quantitative 
(Chapters 3 and 4) and qualitative analyses.
5.2 Experimental
Reagents
(a) Low ionic strength solution (LISS) Ebuffered glycine
solution! was supplied by Sheffield Blood Transfusion
Service (BTS) and used as the FIA carrier stream and as the 
red cell (sample) diluent.
(b)Human polyclonal and mouse hybridoma monoclonal <B*'?> 
anti-A and anti—B anti sera were supplied by BTS and used as 
supplied.
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(c) Human red cell samples (in EDTA anti-coagulant) were 
obtained -from BTS together with their ABO grouping as 
determined by an automated system.
Apparatus
The FIA system employed in these experiments was as 
described in Chapter 2.-
5-3 Static Experiments
Initial experiments were performed in an identical 
manner to the tile method<10>, in order to gain -familiarity 
with the technique and to assess the relative potency o-f 
both the polyclonal and monoclonal antibodies in causing 
agglutination o-f the red cells. For this procedure the human 
blood samples were centri-fuged and the red cells diluted 10X 
with LISS prior to use. One drop o-f the diluted red cells 
was then spotted onto a tile and mixed with one drop of 
serum (anti—A and anti—B in turn). The time for agglutinate 
formation and the amount of agglutinate formed were then 
monitored.
Results obtained by the tile method confirmed the 
blood groups by both polyclonal and monoclonal antibodies. 
Of interest however was the time required for agglutination 
to occur and the amount of agglutinates formed. Using the 
above method it was found that the agglutination was heavier 
and faster using monoclonal antibodies. The time for the 
reaction to develop with the monoclonal antibodies was 2—3 
minutes as compared with approximately 5 minutes when using
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polyclonal antibodies. The results obtained a-fter 3 minutes 
are summarised in Table 5.3.
TABLE 5.3
Blood Polyclonal Antibodies Monoclonal Antibodies
Group anti —A anti —B anti —A anti—B
A + — +++ —
B  —  +  —  + + +
AB + + +++ ++
0 - - -
Key : — no reaction
+ weak agglutination
++ agglutination
+++ heavy agglutination
It is clear -from the table that an increase in 
sensitivity and a decrease in reaction time could be 
afforded by using monoclonal antibodies in the -flowing 
system.
5.4 Stop—Flow Merging Zones FIA
The static method described above was adapted to 
FIA using a merging zones manifold as shown in Figure 5.1 
The two carrier streams (LISS) were pumped at 0.5 ml.min- *. 
Suspended red cell samples, diluted 10X in LISS, <30 jjlI  > and 
anti-A, anti—B sera (30 p.1 alternately) were simultaneously
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injected into the separate carrier streams. Downstream the 
red cells and serum zones were synchronously merged at a 'T' 
piece and then passed into a mixing coil (9 cm, 1.5 mm 
i.d.). At this stage in the analysis the peristaltic pump 
was switched off and the agglutination reaction allowed to 
develop -for 150 seconds in the wider bored mixing coil. The 
pump was then re—activated and the agglutinates (in the case 
o-f a positive reaction) passed into the -flow through 
detector. The absorbance was constantly monitored at 580 nm 
and the output -fed to an A/D converter and a recorder. The 
mode of detection used to distinguish between positive and 
negative samples was an 'in—house' technique, and is based 
on the technique of Y—residuals<ai>. The detection method 
may be better understood by studying the peak profiles in 
Figure 5.2 for both positive and negative samples.
Figure 5.2a is a recorder trace obtained from a 
negative (no) reaction between sample red cells and anti—A 
serum. The peak profile is smooth and typical of a transient 
response. Since the peak profile is smooth it is indicative 
that no agglutination reaction has occured, and as such the 
sample cannot be from a person belonging to group A or AB.
Figure 5.2b is a recorder trace obtained from a 
positive reaction between sample red cells and anti—A serum. 
As is clearly seen, the peak profile is very noisy and 
distorted, due to agglutinate formation between the sample 
and serum, passing through the detector. Thus the mode of 
detection employed here is used to amplify and quantify the
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distorted peak output, so as to enable computer control of 
the ABO blood group typing.
An analogue output o-f the above signal is -fed into 
the Apple lie microcomputer via an A/D converter. The 
microcomputer obtains an analogue output six times a second 
and keeps these values in a store, these values being 
obtained when the sample zone is passing through the 
detector. Thus if the sample zone takes 30 seconds to pass 
through the detector the particular peak profile may be 
represented by ISO analogue outputs, and the values obtained 
by the computer in this way are then treated as follows, 
upon completion of an analysis.
(1) point(n) becomes point(n+1) — point(n) tthe gradient 
between points n and (n+1), since the time interval is a 
constant!.
(2) procedure (a) is repeated producing a set of points 
corresponding to a double differential of the original 
output.
(3) a linear regression routine is carried out for <b) vs. 
time.
(4) the y value of the linear regression fit is calculated 
for each x value of the points. The difference (absolute 
value) between the calculated y value and the actual y 
value is added to a store.
(e) the value accumulated in the store (Yre:q) is directly 
proportional to the amount of noise on the original 
trace.
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Using the above method twenty blood samples o-f 
unknown ABO blood group were then analysed, using monoclonal 
anti—A and anti—B antibodies, and the parameters described 
above.
The results are tabulated in Table 5.4, and with 
the exception o-f one result are in total agreement with the 
results obtained by an automated system at BTS. O-f obvious 
interest is the large differences between the YREB values 
tor negative reactions and positive reactions, which thus 
makes this method a viable detection technique. The 
'cut—ott ' point ot the YREQ values may be estimated by 
analysis at known blood group samples prior to the analysis 
ot unknowns.
The one discrepancy in the results (sample no' 6) was in 
the analysis ot an AB blood group, which has both the A and 
B antigen present on the red cell. By reterence to the table 
it is clear that the anti—B serum did not appear to 
agglutinate the red cells, and thus gave a talse negative 
reaction. By reterence to Table 5.3 it may be seen that the 
agglutination reaction between blood group AB and anti—B 
serum is not as potent as the other agglutination reactions. 
A possible way ot overcoming this is to allow suspected AB 
samples a longer time in the reaction coil in order to allow 
the agglutination reaction to proceed turther.
Thus, this preliminary study at blood grouping 
techniques using FIA is satisfactory. With the use ot 
on-line dilution and stream splitting this procedure would
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BLOOD GROUP
Sample No # Antibody________YRgB_______ +/— _____FIA BTS
1 A 0.2441 - B B
B 0.7715 +
2 A 1.1903 + a A
B 0.2245
3 A ‘ 0.2719 - 0 0
B 0.2904
4 A 0.2214 - 0 0
B 0.2961
5 A 1.5755 + A A
B 0.2757
6 A 0.9755 + A AB~
B 0.2403
7 A 0.8184 + A A
B 0.2315
8 A 1.0876 + A A
B 0.2431
9 A 0.2780 - 0 0
B 0.1960
10 A 0.2178 - B B
B 0.7083 +
11 A 0.2233 - 0 0
B 0.2452
12 A 0.3114 - 0 0
B 0.2847
13 A 1.3031 + A A
B 0.3167
14 A 0.8437 + AB AB
B 0.9725 +
15 A 0.9226 + A A
B 0.2758
16 A 0.3811 - B B
B 0.8230 +
17 A 0.8208 + A A
B 0.3940
18 A 1.0080 + A A
B 0.2341
19 A 1.2939 + A A
B 0.3267
20 A 0-4000 - B B
B 1.6060 +
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be suitable -for routine ABO blood group determinations and 
also as a rapid screening procedure. By using stream 
splitting techniques there exists a possibility o-f 
simultaneous analysis of the. A and B antigen, which would 
thus reduce the analysis time per sample, with a subsequent 
increase in sample throughput. A further study would also 
involve a critical appraisal of the detection technique 
currently used in auto—analyser systems and the 'in—house' 
detection technique described above.
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'£0
1ST
SL7. = 5
dt* = "dvm; i7" . A p p e n d i x  I
RS* = ""
FS$ =
Cl* = ""
PA7. = 1 
X = 256 * SL7.
IC = 49152 + X 
SN = IC + 16 
O FI = IC + 32
O PA = IC + 96
SO = IC + 192 
O SR = 49295 + SL7. * 16
O PE = 1144 + SL7.:DU = 1272 + SL7.
O EOS = 1912 + SL7.
0 CALL FI
O CALL IC
O HOME
POKE 49315,255 
O POKE 49314,0
O VTAB 12s PRINT "PLEASE WAIT - LOADING TIMING PROGRAM"
O POKE 49313,6: REM SET VALVE TO LOAD POSITION AND ALSO START THE PUMP
O PRINT CHR* (4)"BLOAD MINUTES"
O HOME
0 REM MERGING 3 PROGRAMS ,SEE MENU
O VTAB 5: PRINT "***************************************"
O PRINT "* *"
O PRINT "* 1) MAXM PEAK HEIGHT MEASUREMENTS *"
O PRINT "* *"
O PRINT "* 2) STOPPED FLOW KINETIC MEASUREMENTS*"
O PRINT "* *"
O PRINT "* 3) TRANSIENT PEAK MEASUREMENTS *"
O PRINT "* *"
O PRINT "***************************************"
O VTAB 20: INPUT "SELECTION ? ";G
O VTAB 23: INPUT "ARE YOU WORKING IN THE SINGLE CHANNEL OR MERGING ZONES MODE
SC OR MZ) ? ";AH*
O REM **** PROGRAM MAX PK HT ****
O REM *)** APPLESOFT WITH DOS ***
O HOME
O VTAB 6: PRINT "***************************************"
O PRINT " ********************************* "
O PRINT
O PRINT
O IF G = 2 GOTO 470
O IF G = 3 GOTO 480
O PRINT " MAXM.PEAK.HT.MEASUREMENTS ": GOTO 490
O PRINT " STOPPED FLOW KINETIC MEASUREMENTS": GOTO 490
O PRINT " TRANS PEAK MEASUREMENTS "
O PRINT
O PRINT " USING FLOW INJECTION ANALYSIS "
O PRINT
O PRINT
O PRINT " BY: ARWEL HUGHES"
O PRINT
O PRINT
O PRINT " ********************************* "
O PRINT "***************************************"
0 REM EXPLANATION OF VARIABLES
O REM ST = STOP TIME (IN SECONDS)
O REM ME = MEASUREMENT TIME (IN SECONDS)
O REM AB= ABSORBANCE
O REM PE =PEAK HEIGHT (DVM READING)
O REM MP = MAXM.PEAK HT.
O REM BL= BASE LINE (DVM READING)
O RP* = "PRESS RETURN TO CONTINUE "
0 VTAB 23: PRINT RP*: INPUT "";PO$
O POKE 49313,4: REM RELEASE PRESSURE BUT VALVE STILL ACTIVATED
O FOR T = 1 TO 16:RS* = RS* + " ": NEXT T
O D* = "": REM D*=CTRL D
O REM
O REM SETTING UP RUN PARAMETERS
0 REM DE=DELAY, ST = STOP ,ME = MEASUREMENT
O HOME
O INPUT "RUN NUMBER (CODE) =";QW*
O PRINT : INPUT "DATE = ";DA*
0 VTAB 4: INPUT "WHAT IS THE ABSORBANCE RANGE ON DETECTOR ? " ; WE
O VTAB 8: INPUT "WHAT IS THE RANGE ON RECORDER (MV)? " ; ER
0 VTAB 12: INPUT "WHAT IS THE DVM RANGE ? " ; RT
O VTAB 16: INPUT "SPECIAL COMMENTS (FLOW RATE ETC ) ?";SC*
O VTAB 24: INPUT " *** ARE THE ABOVE SETTINGS OK (Y OR N) ”;X*
O IF X$ = "N" THEN GOTO 750 
O DIM X (20)
O HOME
0 PRINT : INPUT "HOW MANY STANDARDS ARE THERE ? ";SSTD: PRINT : INPUT "WHAT U
TS ARE THE VALUES IN ? ";PP*: PRINT
0 INPUT "HOW MANY REPEATS PER STANDARD ? ";RPTS: PRINT : INPUT "HOW MANY REF'E
S PER UNKNOWN ? ";RUEN:U = 1 1
0 FOR I = 1 TO SSTD: PRINT "VALUE OF STANDARD " ; I ; " IN ";PP*: INPUT X(I): PRI
: NEXT
0 VTAB 24: INPUT "ARE THE ABOVE VALUES CORRECT ? ";X*
0 IF LEFTS (X*,l) = "N" GOTO 850: HOME 
0 HOME
0 INPUT "HOW MANY SAMPLES ARE THERE TO BE ANALYSED ?";N0 
O VTAB 4: INPUT "WHAT IS THE DELAY TIME (IN SECONDS) ?";DE 
O IF G = 2 GOTO 970
0 VTAB 8: INPUT "WHAT IS THE REQUIRED STOP TIME (IN SECONDS) ?";ST
5 M2 = INT (ST / 60):Z2 = ((ST / 60) - M2) * 60 
O GOTO 980
0 VTAB 8: INPUT "HOW MANY SECONDS AFTER STOPPING THE PUMP DO YOU REQUIRE THE 
RST DVM READING ? "; ST 
O IF G = 2 GOTO 1020
O IF G = 3 GOTO 1030
00 VTAB 12: INPUT "WHAT IS THE REQUIRED MEASUREMENT TIME (IN SECONDS) ?";ME
10 GOTO 1040
20 VTAB 12: INPUT "WHAT IS THE MEASUREMENT TIME BETWEEN THE TWO READINGS (IN
CONDS) ?";ME: GOTO 1040
30 VTAB 12: INPUT "HOW MANY SECONDS AFTER SAMPLE INJECTION DO YOU REQUIRE THE
VM READING ? ";ME: GOTO 1040
40 VTAB 20: INPUT "*** ARE THE ABOVE SETTINGS OK (Y OR N)? ";X*
50 IF X$ = "N" THEN GOTO 910 
60 HOME
70 VTAB 2: INPUT "IS SAMPLER PROBE IN WASH SOLUTION (Y OR N> ? " ; PR*
80 IF PR* = "N" THEN POKE 49313,20: FOR H = 1 TO 400: NEXT H: POKE 49313,4 
90 VTAB 6
00 INPUT "HOW MANY SECONDS FOR SAMPLE TO REACH INJECTION POINT FROM AUTOSAMPL 
? " ; AS
10 VTAB 8: INPUT "FOR HOW LONG MUST VALVE BE IN INJECT POS'N ? ";VI
20 VTAB 10
30 INPUT "WHAT IS THE DELAY BETWEEN SAMPLES ? ";SD
40 IF AH* = "MZ" THEN VTAB 14: INPUT "FOR HOW LONG MUST PUMP BE ACTIVATED EG
COMMON REAGENT TO FILL LOOP ? ";CR
50 IF AH* = "MZ" THEN VTAB 17: PRINT "PLACE DELIVERY TUBE IN COMMON REAGENT
41 V I V  /y 4 V 4^ X cx
70 IF AH* = "MZ" THEN GET JK*
80 POKE 49313,4
90 VTAB 23: PRINT "PLACE SAMPLE TRAY IN POSITION AND PRESS ANY KEY TO START R
II
00 GET JK*
lO REM ****************************************
20 REM DIMENSION ARRAYS FOR FINAL OUTPUT
30 DIM AB(NO)
40 DIM PE(NO)
50 REM ***************************************
60 REM MAIN PROGRAM
70 CALL (832)
80 SL = ME - (AS + 2)
90 MI = ME - (AS + VI + 2)
00 IF AH* = "MZ" THEN VR = (DE - VI):NS = (ME + SD) - (AS + 2):ACR = 3D - (CR
2)
10 SR = ME - NS
■20 REM ****************************************
•30 REM PROGRAM LOOP STARTS HERE
40 FOR I = 1 TO NO
50 POKE 49313,4: REM DE-ACTIVATOR FOR LOOP
60 IF I = 1 GOTO 2980
70 POKE 49313,5: REM INJECTNEXT SAMPLE
■80 FOR T = 1 TO 200: NEXT T: POKE 49313,4
.90 POKE 816,0: POKE 817,0
00 HOME
10 MP = O
20 PRINT " SAMPLE NUMBER ";I
30 IF G = 2 GOTO 1460
40 GOSUB 2530: REM GET BASE LINE VALUE
50 IF DE = O GOTO 1530
60 IF PEEK (817) < VI THEN 1460
70 POKE 49313,22: FOR S = 1 TO 300: NEXT S: POKE 49313,4
80 IF DE = VI THEN 1510
90 POKE 816,0: POKE 817,0
00 IF PEEK (817) < VR THEN 1500
10 VTAB 2: PRINT " ***** STOP THE PUMP ***** "
20 POKE 49313,0: REM SWITCH PUMP OFF
30 IF ST = O THEN 1600
40 POKE 816,0: POKE 817,0: POKE 818,0
50 IF PEEK (818) < M2 THEN 1550
55 IF PEEK (817) < Z2 THEN 1555
60 IF G = 2 THEN LM = 0:CI$ = "R,DVM": CALL SN: VTAB 7: PRINT "FIRST DVM READ
G = "; VAL (RS$) * 1000;" MV":FI = VAL (RS£> * 1000: GOTO 1590
70 VTAB 4: PRINT " ***** START THE PUMP *****"
80 POKE 49313,4: REM RE—ACTIVATE THE PUMP
90 REM ****************
00 POKE 816,0: POKE 817,0
10 IF G = 2 GOTO 2660: IF G = 3 GOTO 2660
20 IF G = 3 GOTO 2660
30 FOR R = 1 TO 400: NEXT R
40 POKE 49313,4
50 GOSUB 2600
60 IF PEEK (817) < VI GOTO 1650
70 POKE 49313,22
80 FOR R = 1 TO 300: NEXT R
90 POKE 49313,4
00 POKE 816,0: POKE 817,0
10 GOSUB 2600
20 IF PEEK (817) < MI THEN 1710
30 IF I = NO GOTO 1790
40 POKE 49313,20
50 FOR R = 1 TO 300: NEXT R
60 POKE 49313,4
90 IF PEEK (817) < SL GOTO 1780 
00 IF G > 1 GOTO 2930 
10 IF G = 3 GOTO 2930
20 VTAB 9: PRINT " ** PEAK MAXM. = ";2 * MP; " A.U"
30 POKE 49313,4
40 REM ****************
50 REM ****************
60 AQ = MP * 1000: REM CHANGE VOLTS TO MV
70 AG = INT (AQ * 10000 + .5) / 10000
80 P E (I) = AQ
90 PH = (2 * MP) - (2 * BL)
00 PH = INT (PH * 10000 + 0 . 5 )  / 10000
10 A B (I) = PH
20 VTAB 12: PRINT "*** ACTUAL PEAK HEIGHT = ";PH;" A.U"
30 ET = DE + ST + ME
40 IF G = 2 THEN P E (I) = ET
50 VTAB 16: PRINT " ** ELAPSED TIME = ";ET;" SECONDS
60 IF I = NO GOTO 2050
70 POKE 49313,4
80 POKE 816,0: POKE 817,0
90 IF PEEK (817) < SD THEN 1990
00 FOR D = 1 TO 2000: NEXT D
10 NEXT I
>20 REM ****************************************
>30 REM PRINT-OUT OF RESULTS
>40 POKE 49313,4
>50 VTAB 23: PRINT RFT: INPUT " "; U*
60 HOME
70 VTAB 4: INPUT "DO YOU REQUIRE A PRINT-OUT OF THE RESULTS (Y/N)? "
80 FLASH
90 VTAB 8: PRINT "IF (Y) MAKE SURE PRINTER IS ON-LINE”
00 NORMAL
10 VTAB 16: PRINT RP*: INPUT "";U*
20 IF M* = "N" GOTO 2140 
30 PRINT CHR* (4);"PR£1"
40 HOME
50 IF G = 1 THEN LM = 0 :  PRINT "MAXIMUM PEAK HEIGHT MEASUREMENTS ":
60 IF G = 2 THEN LM = O: PRINT "STOPPED FLOW KINETIC MEASUREMENTS":
70 IF G = 3 THEN LM = O: PRINT "TRANSIENT PEAK MEASUREMENTS": PRINT
80 PRINT "RUN NUMBER (CODE) = " ; QW*
90 PRINT "ABSORBANCE RANGE ON DETECTOR =";WE
00 PRINT "RECORDER RANGE (MV) = ";RT
10 PRINT "DVM RANGE (MV) = ";ER
20 PRINT
•30 PRINT "DELAY TIME = ";DE;" STOP TIME = ";ST 
40 PRINT "MEASUREMENT TIME = ";ME
•50 PRINT "***************************************"
60 IF G = 2 THEN GOTO 2300
70 PRINT "SAMPLE NO. ";" ABSORBANCE ";" DVM PK.HT/MV"
-80 PRINT "-----------  ";"----------- ";"  "
90 GOTO 2320
•00 PRINT "SAMPLE NO. ";" SLOPE A.U/MIN ";" ET/SEC"
>10 PRINT "-----------" ; " ----------------  "; " -"
-20 FOR I = 1 TO NO
>30 HTAB 4: PRINT I ,A B (I),PE(I)
•40 NEXT I
50 PRINT CHR* (4);"PR£0"
•60 PRINT : PRINT : INPUT "DO YOU WANT TO SAVE THE DATA ON DISC ?" ;P*
70 IF LEFT* (P*,l) = "N" THEN 2490 
80 FLASH
90 PRINT : PRINT "PLEASE ENSURE DATA DISC IS IN DRIVE 1"
00 NORMAL
10 D* = CHR* (4): PRINT : PRINT : INPUT "ENTER FILENAME = ";F*
20 PRINT D*;"OPEN";F*; " , D 1" : PRINT D*;"WRITE ";F*
;M*
PRINT
PRINT
50 PRINT NO: PRINT WE: PRINT RT: PRINT ER: PRINT DE: PRINT ST: PRINT ME 
60 FOR I = 1 TO NO: PRINT A B (I): PRINT P E (I): NEXT 
70 PRINT G: PRINT QW*: PRINT DA*: PRINT SC*
80 PRINT D*;"CLOSE"
90 POKE 49313,4 
00 END
10 REM ****************************************
20 REM SUB-ROUTINE TO OBTAIN BASE-LINE VALUE 
30 Cl* = "R,DVM"
40 CALL SN
50 BL = VAL <RS*>
60 VTAB 7: PRINT " *** BASE-LINE VALUE ";2 * BL;” A.U"
70 RETURN
80 REM ****************************************
90 REM SUB-ROUTINE TO OBTAIN DVM READINGS DURING MEASUREMENT TIME 
00 CI$ = "R,DVM"
10 CALL SN
20 S = VAL (RS*>
30 IF S > MP THEN MP = S
40 RETURN
50 REM ****************************************
60 IF PEEK (817) < NS THEN 2660
70 IF ME = NS THEN 2720
80 IF I = NO GOTO 2700
90 POKE 49313,16: FOR T = 1 TO 300: NEXT T: POKE 49313,0
00 POKE 816,0: POKE 317,0
10 IF PEEK (817) < SR THEN 2710
20 CI$ = "R,DVM": CALL SN
30 IF ME = NS THEN POKE 49313,16: FOR T = 1 TO 300: NEXT T: POKE 49313,0
40 FOR T = 1 TO 300: NEXT T
50 POKE 49313,4: REM START THE PUMP
60 VTAB 9: PRINT "SECOND DVM READING = "; VAL (RS*) * 1000;" MV":SE = VAL (R
) * 1000
70 SE = SE / 1000:FI = FI / 1000
80 AB = (2 * SE - 2 * FI) / (T / 60):AB = INT (AB * 10000 + 0.5) / iOOOO:AB(I
= AB
90 VTAB 12: PRINT " SLOPE = ";AB;" A.U/MIN"
00 ET = DE + ST + ME 
10 PE(I) = ET
20 VTAB 16: PRINT " ELAPSED TIME = ";ET;" SECONDS"
30 POKE 816,0: POKE 817,0
40 IF I = NO GOTO 2050
50 IF ACR = 0 THEN 2870
60 IF PEEK (817) < ACR THEN 2860
70 POKE 49313,12: REM PI AND P2 ACTIVATED
80 POKE 816,0: POKE 817,0
90 IF PEEK (817) < CR THEN 2890
00 POKE 49313,4: POKE 816,0: POKE 817,0
10 IF PEEK (817) < 2 THEN 2910
20 NEXT I
30 REM **************************************
40 MP = VAL (RS*): VTAB 9: PRINT "*** TRANS PEAK = ";2 * MP;" A.U"
50 AQ = MP * 1000: REM CHANGE VOLTS TO MV:PE(I)=AQ
60 P E (I) = AQ
70 PH = (2 * MP) - (2 * BL):A B (I) = PH: VTAB 12: PRINT " ACTUAL TRANS PK HT = 
' ;PH;" A.U": GOTO 1930
80 POKE 49313,20: FOR Y = 1 TO 300: NEXT Y: POKE 49313,4
90 POKE 816,0: POKE 817,0
>00 IF PEEK (817) < AS THEN 3000
10 GOTO 1370
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A Model Immunoassay Using Automated Flow Injection Analysis
Paul J. Worsfold* and Arwel Hughes
Department of Chemistry, Sheffield City Polytechnic, Pond Street, Sheffield, S1 1WB, UK
A model immunoassay between concanavalin A (antibody) and yeast mannan (antigen) was investigated 
using a microcomputer-controlled flow injection analysis (FIA) manifold with turbidimetric detection at 400 
nm. The automated injection procedure gave good precision for a turbidimetric method and the stop-flow 
merging zones technique gave an acceptable sample throughput (50 samples per hour) with minimum 
consumption of sample (30 pi). The system described could therefore be used routinely for immunoprecipitin 
analysis in clinical laboratories, e.g., IgG in human serum, and also to study kinetic aspects of such reactions.
Keywords: Model immunoassay; concanavalin A; automation; merging zones; stop-flow flow injection 
analysis
The first quantitative determ ination of proteins based on an 
immunoprecipitin reaction was reported by Heidelberger and 
Kendall1 in 1935. This was followed in 1959 by the first such 
analysis of direct clinical relevance, the determination of 
human plasma proteins, reported by Schultze and Schwick.2 
The current importance of the immunoprecipitin technique for 
the analysis of proteins has been emphasised by the 
development of an autom ated immunoprecipitin analyser by 
Ritchie et al.3 and the subsequent use of laser nephelometry to 
increase the sensitivity of the m ethod.4 One attraction of the 
immunoprecipitin technique over other immunochemical 
methods is the ease with which the procedure can be 
automated, which contributes to low relative standard 
deviations (RSDs) and good inter-laboratory correlation.5 The 
limitations imposed by the high background scattering of the 
samples and the time taken for the reaction to reach 
equilibrium can be overcome by measuring the rate of reaction, 
typically over a timespan of 30-60 s.6
Flow injection analysis (FIA ), a technique based on 
unsegmented continuous flow,7 provides an attractive high­
speed, low-cost alternative to existing instrumentation for the 
study of immunoprecipitin reactions.8 The FIA manifold is 
very flexible (and therefore appropriate for laboratories 
dealing with small sample batches and a wide range of reaction 
chemistries), it can be easily autom ated and used for rate 
measurements9 and in the merging zones mode the consump­
tion of sample and reagent is minimised.1'1
This paper describes the results of a study of a model 
immunoprecipitin reaction between concanavalin A (the 
model antibody) and yeast mannan (the model antigen) using 
a stop-flow merging zones FIA manifold, and is a continuation 
of previously reported preliminary studies.8 Details of the 
complete automation of the system using a microcomputer are 
also presented.
Experimental
Reagents ^
An aqueous buffer solution containing sodium acetate (10 
h i m ), sodium chloride (0.1 m ) and Brij-35 (0.3% m/V) was 
adjusted to pH 6.2 with acetic acid (1 m ).
Concanavalin A was obtained as a lvophilised powder from 
Canavalia ensiformis (jack beans: Fluka) and reconstituted in 
the above buffer solution (2 mg m l-1).
Yeast mapnan was obtained after extraction from yeast by 
the Cetavlon method (Sigma) and standards were prepared in 
the above buffer solution over the range 0.1-20.0 mg ml-1.
All solutions were filtered through a fine sintered-glass 
funnel before use and were stored at 4 °C when not in use. 
Fresh solutions were prepared weekly.
* Present address; Department of Chemistry. University of Hull. 
Cottingham Road. Hull. HU6 7RX. North Humberside, UK.
Instrumentation and Procedures
Static experiments
These were performed using a microprocessor-controlled U V - 
visible spectrophotometer (Perkin-Elmer 550S) and micro 
glass cells (Hellma 6082-Green). Equal volumes (0.2 ml) of 
concanavalin A and a range of yeast mannan standards were 
manually mixed in a micro glass cell and the resultant turbidity 
of the solution was monitored in order to establish the 
optimum wavelength for analysis and a suitable reaction time 
for the flow-through method described below. The zone of 
equivalence for the interaction was also determ ined using this 
static system.
Stop-flow merging zones FIA
The manifold used for the merging zones flow injection 
experiments is shown in Fig. 1. The two buffer streams were 
pumped at 0.5 ml min_ l, using a peristaltic pump (Ismatec 
Mini S-840), through polypropylene tubing (0.5 mm i.d.). 
Concanavalin A (30 pi) and yeast m annan (30 pi) were 
simultaneously injected into separate buffer streams using an 
autom ated PTFE rotary valve. Further downstream the 
concanavalin A and yeast mannan zones were synchronously 
merged at a T-connector and then passed through a mixing coil 
(25 cm) into a flow-through cell (7.9 pi volume; 10 mm path- 
length) housed in a spectrophotom eter (Varian VUV-50). The 
turbidity was constantly monitored at 400 nm and the output 
fed to a recorder and an analogue to digital converter 
(Hewlett-Packard 3438A; 3.5 digits).
The rate of reaction was determined by stopping a segment 
of the merged concanavalin A and yeast mannan zones in the 
flow cell and performing a two-point kinetic analysis. This was 
achieved by switching off the peristaltic pump 14 s after 
sample injection (delay time), measuring the turbidity 30 and 
60 s later and then reactivating the pump to flush out the 
reaction mixture.
Concanavalin A
Flow-rate/ 
ml min-1
(antibody)
--- 1I------------- 1
, Buffer , 0.5 25 cm |Waste
400 nm
0.5Buffer
25 °C
Yeast mannan (antigen)
Fig. 1. Merging zones manifold for the immunoprecipitin reaction 
between concanavalin A (30 pi) and yeast mannan (30 pi) introduced 
into separate buffer streams (pH 6.2). Mixing coil, 25 cm x 0.5 mm 
i.d.; dispersion. 15
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Flow rate/ 
ml min-1Human serum IgG
0.5PEG - NaCI
Mixing coil
340 nm Waste
0.5PEG - NaCI 20 cm
Goat anti-human
IgG antiserum
Fig. 1. Merging zones manifold for the immunoprecipitin reaction between human IgG (30 pi) and goat anti-human IgG antiserum (30 pi) 
introduced into separate PEG - NaCI carrier streams. The dispersion of the human IgG in the manifold was 11
coil (20 cm) into a flow-through cell (volume 7.9 pi, path 
length 10 mm) housed in a spectrophotometer (Varian 
VUV-50). To ensure complete mixing of the merged zones a 
close-packed glass bead column (4 cm x 1.5 mm i.d.; bead size 
80 mesh) was incorporated into the mixing coil. The turbidity 
was constantly m onitored (340 nm) and the output fed to a 
recorder and an A/D converter (HP 3438A; 3.5 digit).
The rate of reaction was determ ined by stopping a segment 
of the merged serum and antiserum zones in the flow cell and 
performing a two-point kinetic analysis. This was achieved by 
switching off the peristaltic pump 14 s after sample injection, 
measuring the turbidity 30 and 60 s later and then reactivating 
the pump to flush out the reaction mixture. Complete 
automation of the FIA  manifold and data collection and 
treatm ent were as previously described.9*10
Results and Discussion 
Static Experiments
A  wavelength scan (280-520 nm) for the antiserum, a human 
serum standard and the resultant immunoprecipitin complex 
‘showed that turbidim etric detection at 340 nm gave the 
optimum signal to background ratio for the complex. A 
human serum IgG standard (1778 mg dl-1) was then analysed 
at varying dilutions and the resultant data are given in Table 1. 
It shows that serum dilutions of 800-fold and more gave rise to 
the condition of antibody (antiserum) excess and that a serum 
dilution of only 500-fold gave rise to the condition of antigen 
(serum) excess. As the concentration of the standard used was 
above the upper limit of the normal clinical range, a dilution of 
800-fold was chosen for serum standards and samples in order 
to provide maximum sensitivity commensurate with the 
condition of antibody excess being met for the majority of 
samples. Equal volumes of serum and antiserum were used in 
the above experiments to facilitate the transfer of the reaction 
to a merging zones FIA  manifold.
A series of human serum IgG standards covering the range
0-1778 mg dl-1 was then analysed by the above procedure 
after 800-fold manual dilution. The correlation coefficient (r) 
for the resultant calibration graph was 0.997, indicating that 
the top standard was within the antibody excess region and 
that the reaction conditions were suitable for a practical 
analytical method based on FIA.
Stop-flow Merging Zones FIA
Experiments were initially carried out in the antibody excess 
region only (0-1778 mg d l-1 of IgG), using dilutions of 80-fold 
for the antiserum and 800-fold for the standards and samples. 
The results obtained for five replicate injections of each 
standard are shown in Table 2 and indicate an acceptable 
precision at the higher end of the range. Owing to the long 
induction period necessary for the development of the 
immunoprecipitin reaction, however, the sensitivity and 
reproducibility are poor at lower serum IgG concentrations
Table 1. Increase in turbidity versus human serum standard (1778 
mg dl-1) dilution. All experiments performed in duplicate
Turbidity,
Serum dilution absorbance units
1000   0.127
900   0.133
800   0.162
700   0.166
600   0.165
500   0.132
Table 2. Human serum IgG concentration versus increase in turbidity 
using a merging zones FIA manifold. All results are means of five 
experiments
Standard Relatve
Slope/ deviation/ standard
Serum IgG/ absorbance absorbance deviation,
mg dl-1 units min-1 units min-1 %
0 0 0 —
266 0 0 —
533 0.0053 0.0008 15.1
889 0.0147 0.0003 2.0
1155 0.0176 0.0012 * 6.8
1422 0.0233 0.0013 5.6
1778 0.0275 0.0013 2.5
under the conditions used. This could be improved by 
increasing the stop time in the flow cell or by reducing serum 
and antiserum dilution, but this would lead to longer analysis 
times or higher reagent costs. U nder the conditions described, 
the sampling rate was 40 samples per hour and the reagent cost 
was less than lp  per analysis (i.e., less than 1 pi of undiluted 
antiserum per assay).
The between-batch reproducibility of the technique is 
shown in Fig. 2. The error bars indicate the range for the 
pooled data, which consisted of five results for each standard 
on the first run and five results for each standard on the second 
run 1 week later. Each point represents the mean of the ten 
pooled results. The shape of the calibration graph is charac­
teristic of immunoprecipitin reactions, with very slow reaction 
rates at low concentrations, rising through a linear region to a 
plateau at the equivalence point. This shape was shown to be 
reproducible over several weeks and therefore a single-point 
calibration can be used when required, as with commercial 
rate nephelom eters.6 The excess of antigen can be determ ined 
by dilution of suspect samples or by the use of single channel 
stop-flow F IA .10
Quantitation of Serum Samples
For the analysis of nine human serum samples and the US 
National Reference Preparation, IgG standards covering the 
range 0-3556 mg dl-1 were used, with the antibody excess 
region covered by six standards up to 2844 mg d l-1 . A
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Table 3. Turbidity versus yeast mannan concentration using a 
single-channel FIA manifold. All results are means of five 
experiments
Slope/ Standard deviation/
Yeast mannan/ absorbance units absorbance units RSD,
mg ml-1 min- 1 min 1 %
0.00 -0 .0 0 3 8 0.0020 —
0.02 0.0189 0.001 1 ' 5.8
0.05 0.207 1 0.006 1 2.9
0.07 0.357 3 0.021 6 6.0
0.10 0.540 1 0.009 1 1.7
0.15 0.794 1 0.009 1 1.1
0.20 0.9318 0.029 5 3.2
0.40 1.0560 0.0806 7.6
0.50 1.157 6 0.163 3 14.1
0.70 1.0941 0.204 8 18.7
1.00 0.556 2 . 0.103 0 18.5
2.00 0.2527 0.020 8 8.2
4.00 0.104 5 0.0105 10.0
Tem perature control is essential if reproducible results are 
to be obtained, and for this work the temperature was 
controlled at 25 °C. A limited number of experiments carried 
out at 30 °C, however, suggested that there was an improved 
sensitivity at the higher tem perature due to an increased rate 
of reaction. One practical problem arising from stop-flow 
work involving turbidimetric detection is occlusion of the cell 
windows, which leads to base-line drift. This can be overcome 
by the incorporation of an extra channel, pumping dilute nitric 
acid through the flow cell, which can be activated via the 
microcomputer when required.
An alternative to the stop-flow approach is to increase the 
residence time of the merged zones in the manifold by 
increasing the length of the mixing coil and reducing the 
flow-rates. This continuous flow approach does not require 
microcomputer control but, in the concanavalin A - yeast 
mannan reaction, an acceptable sensitivity is possible only 
with excessively long analysis times.
Single-channel FIA Manifold
The major disadvantage of this manifold design is the 
continuous consumption of a potentially expensive reagent; 
the attraction is that the results clearly distinguish between the 
conditions of antibody excess and antigen excess. As the 
injected sample zone (yeast mannan) travels through the 
mixing coil physical dispersion in the carrier stream (conca­
navalin A) occurs, and this results in a continuous sample 
concentration gradient from zero to some maximum value 
within the mixing coil. In the region of antibody excess the 
detector response will therefore be in the form of a single peak 
with a maximum at the point of maximum sample concentra­
tion. In the region of antigen excess, however, the output will 
be in the form of a double peak with a trough at the point of 
maximum sample concentration. The same effect occurs in the 
unsegmented region of segmented continuous flow analy­
sers.11
In order to enhance the sensitivity of the single-channel 
approach a stop-flow technique was used, with a delay time of 
10 s and a two-point kinetic measurement 20 and 50 s later. 
This delay time was chosen so as to stop the zone of maximum 
sample concentration in the flow cell. The results are given in 
Table 3 and, as expected, show an increased sensitivity 
compared with those obtained using a merging zones mani­
fold. In this instance the condition of antigen excess is 
indicated by a “spike" on the output when the pump is 
reactivated and more favourable concentration ratios for 
complex formation are swept through the flow cell.
Conclusions
Flow injection analysis provides a rapid, economical means of 
fully automating immunoprecipitin reactions. Owing to the 
simplicity of the manifold design it can also be easily modified 
to accommodate a wide range of chemical reactions, on-line 
processes and detection systems. Using the stop-flow merging 
zones approach sample and reagent consumption are kept to a 
minimum (30 pi) and quantitative results are obtained within
1-2 min of injection. For the concanavalin A - yeast mannan 
reaction the sampling rate was 50 samples per hour and a 
typical correlation coefficient for the analytically important 
antibody excess region of the calibration graph was 0.9808. 
The use of a single-channel manifold offers enhanced 
sensitivity and clearly distinguishes between antibody excess 
and antigen excess.
There are differences between the model system discussed 
above and immunoprecipitin assays: for example, immuno­
precipitin interactions are normally carried out at a pH of 
7.0-8.5, concanavalin A is a m etalloprotein and requires a 
complement of calcium and manganese ions and antibodies 
are conventionally obtained in a heterogeneous matrix. It is 
not unreasonable to assume, however, that the technique 
described above will also - be applicable to routine 
immunoprecipitin analysis, e.g., the determ ination of human 
IgG in serum, and work is at present being carried out in this 
area.
The authors thank the Science and Engineering Research 
Council for their financial support for one of them (A .H .) and 
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Monitoring of Immunoprecipitin Reactions Using Flow Injection 
Analysis
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The quantitative determ ination of proteins by immunoprecipi- 
tation was first reported in 1935. Since that time a num ber of 
more sensitive immunoassay techniques have been developed. 
e.g., radioim m unoassay, enzyme immunoassay and fluores­
cence imm unoassay, but in applications where high sensitivity 
is not required, e.g ., for the analysis of most clinically
between bivalent antibody and m ultoalent antigen molecules, 
which induce light scattering, so that an increase in turbidity is 
obsersed. The relationship between the antigen concentration 
and the am ount of antibody precipitated is known as the 
immunoprecipitin curve. It is linear, and therefore quantita­
tive. up to a certain antigen concentration owing to the 
increasing am ount o f  cross-linking between antibody and 
antigen (the antibody excess region). The curve then passes 
through a plateau region (the zone of equivalence) wherein 
equivalent num bers of antibody and antigen binding sites are 
available. As the antigen concentration is further increased, 
there is com petition for antibody binding sites, the average size 
of the aggregates falls and hence light scattering decreases (the 
antigen excess region).
It has previously been reported that flow injection analysis 
(FIA ) coupled with turbidim etric detection provides a precise, 
rapid and simple system for the study of a model im m unopre­
cipitin interaction.2 This paper describes an autom ated merg­
ing zones FIA procedure for the determ ination of a high 
relative molecular mass protein, human serum IgG.via its 
interaction with goat anti-human IgG and based on rate 
turbidim etry.
Experimental
G oat anti-human IgG antiserum (Atlantic Antibodies; 2 ml) 
was prediluted 80 times, and human IgG calibrator serum 
(Atlantic Antibodies) 800 times, with polyethylene glycol 
(40g 1“ 1) - sodium chloride solution (9 g 1~1) as the diluent in 
both instances.
The merging zones manifold used here was as previously 
described.2 In this instance the working antiserum  (30 ul) and 
human serum (30 pi) standards were simultaneously injected 
into separate carrier streams of PEG - sodium chloride solu­
tion pumped at 0.5 ml m in-1 . The two zones were synchro­
nously merged and passed through a coil packed with glass 
beads into the flow-cell of a spectrophotom eter (340nm). A 
segment of the merged zones was stopped in the flow-cell 14 s 
after injection for a period of W's. A two-point kinetic analy sis 
was then perform ed by taking readings 44 and 74 s after 
injection.
A utom ation of the system was as previously described.2 with 
two modifications. Antigen samples were introduced into the 
injection valve automatically via an autosam pler, and a 
separate com puter controlled peristaltic pump was used to 
introduce antibody into the injection valve.
Results
A calibration graph was obtained for human serum IgG over 
the range 11-3556 mg d l-1 . Under the conditions described 
above there was a linear relationship (correlation coefficient
0.985) between reaction rate and IgG concentration over the 
range 0-2844 mg d l-1 and a decrease in reaction rate over the 
range 2844-3556 mg dl “ 1. The relative standard deviations ( "a )
significant serum proteins, detection based on immunoprecipi- 
tation has several advantages. The reaction can be followed by 
use of a simple spectrophotom eter: no label is needed and. 
therefore, the reaction is m onitored directly. Also there is no 
separation stage so the procedure is readily autom ated.
The technique is based on the form ation of aggregates
for within-batch (5 replicates) and between-batch (15 repli­
cates) precision in the antibody excess region were 2 -4 ‘\» and
2 -6 '\.. respectively. These results dem onstrate the characteris­
tic immunoprecipitin response described above and suggest 
that quantitative results can be obtained over a useful clinical 
range. The linear range and sensitivity can be m odified to suit 
particular requirem ents, either by varying the dilution factors 
for the antibody and antigen or by using asynchronous merging 
zones. The sample throughput for human serum  IgG using the 
above manifold was 40 samples h -1. A com parison of the 
analytical performance of the FIA technique with that of 
radial immunodiffusion (RID ) is currently being undertaken 
and will be the subject of a future publication.
Discussion
Refinements to the manifold used to  study a model im m uno­
precipitin reaction2 were made when analysing to  determ ine 
IgG in order to improve the sensitivity o f the reaction and to 
reduce the am ount of expensive antiserum  consum ed. Firstly, 
the carrier stream and the diluent for both antibody and 
antigen contained polyethylene glycol (40 g I-1) in order to  
enhance the formation of large m olecular aggregates and to  
increase the sensitivity. This, in tu rn , increased the sample 
throughput (40 samples h -1), with the results for any sample 
being available less than 2 min after sample injection. The use 
of highly viscous carrier streams, however, led to poor mixing 
between the merging zones, and a drifting signal resulted. This 
tendency was overcome by the introduction of a mixing coil, in 
this instance a packed glass bead colum n, between the 
confluence point and the detector. Secondly, a separate 
autom ated peristaltic pump was used for the delivery of 
expensive antibody into the injection valve (30 pi), in o rder to 
minimise the amount of reagent waste during the loading 
procedure.
The feasibility of using FIA to m onitor im m unoprecipitin 
interactions has been dem onstrated and the results com pare 
favourably with existing techniques in term s of linear range, 
precision, sample throughput and cost. The manifold can easily 
be modified to suit the requirem ents of a particular analysis 
and the application range could be extended to include other 
serum constituents present at sufficiently high concentrations. 
e.g . . certain therapeutic drugs and blood group indicators. The 
sensitivity could be increased by changing the dilution factors 
of the antibody or antigen or bv the use of laser-nephelom etric 
detection. Alternatively, more sensitive hom ogeneous im ­
munoassay techniques, based on enzyme and luminescent 
labels, could be coupled with FIA in order to  provide a cheap, 
easily autom ated immunoassay system with rapid response 
times.
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Determination of Human Serum Immunoglobulin G Using Flow 
Injection Analysis with Rate Turbidimetric Detection
Paul J. Worsfold
Department of Chemistry, University of Hull, Cottingham Road, Hull HU6 7RX, UK 
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An immunological reaction between human serum immunoglobulin G (IgG) and goat anti-human IgG was 
investigated using a fully automated stop-flow merging zones flow injection analysis manifold. Turbidimetric 
detection at 340 nm was used to monitor the rate of reaction. A sampling rate of 40 samples per hour and a 
precision of 2.0-6.8% RSD (relative standard deviation) were obtained for a range of human serum standards. 
Serum samples and a human reference serum were analysed and their IgG concentrations interpolated from 
a second-order fit of the calibration data. The consumption of expensive antiserum was less than 1 pi per 
assay.
Keywords: Human immunoglobulin G; immunoprecipitin reaction; automated flow injection analysis; 
merging zones; rate turbidimetric detection
The immunoglobulins are a group of structurally related 
plasma proteins that m ediate circulating antibody responses. 
There are five classes of human immunoglobulins, of which 
immunoglobulin G (IgG) accounts for 70-75% of the total 
pool.1 Isolated human IgG is a monomeric protein of relative 
molecular mass (Mr) 146000, consisting of two large (heavy) 
polypeptide chains (M r 50000-70000) and two smaller (light) 
chains (Afr 22000), with two antigenic binding sites per 
molecule. The two heavy chains are covalently linked by two 
disulphide bridges and each heavy chain is bound to a light 
chain in a similar manner.
The serum IgG concentration in normal adults lies within 
the range 600-1600 mg d l-1 .2 Depressed or elevated IgG 
levels are useful diagnostic indicators for various conditions, 
and human serum is typically screened semi-quantitatively by 
electrophoresis, with radial immunodiffusion (R ID )3 being 
used subsequently for quantitative purposes on suspected 
abnormal samples. A m ajor limitation of RID , however, is the 
time required (24-48 h) for the antibody - antigen reaction to 
develop.
As a result, various instrumental methods have been 
developed for serum IgG determ ination, based on the 
light-scattering ability of the antibody - antigen complex. 
These include a segmented continuous flow technique using 
an autom ated immunoprecipitin analyser,4 a centrifugal 
analyser procedure5 and a rate nephelometer m ethod.6 One 
restriction to the widespread use of these instrumental 
techniques is the high capital and/or running costs involved.
Flow injection analysis (FIA) has been shown to provide a 
cheap, rapid and autom ated analytical facility that is also 
extremely flexible in its application.7-8 It would therefore be 
appropriate for quantitative serum IgG determination in small 
clinical laboratories. This paper describes such a determina­
tion using a stop-flow merging zones FIA manifold with rate 
turbidimetric detection. The work is a continuation of 
previously reported preliminary studies9 on the reaction 
between human serum IgG and goat anti-human antiserum.
Experimental
Reagents
An aqueous solution of polyethylene glycol (PEG , A/r 6000) 
(40 g I-1) and sodium chloride (9 g I-1) was used for both 
carrier streams in the FIA manifold and as the serum/anti­
serum diluent.
G oat antiserum specific for human IgG (Fc piece) of
nephelometric quality (Atlantic Antibodies, D idcot, Oxford­
shire) was used as the antibody. The original solution 
contained sodium azide (1 g I-1) and was evaluated for 
monospecificity by immunoelectrophoresis. The working 
antiserum was prepared by diluting the goat antiserum (0.3 
ml) with PEG  - NaCI diluent (24.7 ml) giving an 80-fold 
dilution.
Human serum IgG standards were prepared by serial 
dilution (500-1000-fold) of two human serum reference 
materials (Atlantic Antibodies), with quoted values of 1778 
and 3566 mg d l-1 of IgG. A  US National Reference 
Preparation for Specific Human Proteins (C enter for Disease 
Control, A tlanta, G A , USA), with a quoted value of 1128 
mg dl-1 of IgG, was diluted 800-fold and used as a control 
serum. Human serum samples were obtained from Doncaster 
Royal Infirmary and diluted 800-fold before analysis. All 
samples and reagents were stored at 4 °C when not in use.
Static Experiments
These were perform ed using a microprocessor-controlled UV 
- visible spectrophotom eter (Perkin-Elm er 5505) and semi­
micro special optical glass cells (Hellma 6082-Green). In order 
to determine the optimum dilution of the hum an serum 
samples and standards, equal volumes (200 pi) of antiserum 
and a range of dilutions of the 1778 mg dl-1 human serum 
standard were manually mixed in a semimicro glass cell and 
the resultant turbidity was monitored. A  10-s delay time was 
used to allow for mixing and the reaction rate monitored over 
the next 30 s at 340 nm. Having determ ined a suitable dilution 
factor to ensure an excess of antibody (800-fold), a range of 
human IgG standards (0-1788 mg dl-1) were analysed by the 
above method.
Stop-flow Merging Zones FIA
The manifold used for the FIA experiments is shown in Fig. 1 
and is a modified version of a previously described system.9-10 
The two PEG - NaCI carrier streams were pumped at 0.5 
ml min-1 , using a peristaltic pump (Ism atec Mini S-840), 
through polypropylene tubing (0.5 mm i.d.). Working anti­
serum (30 pi) and human serum standards (800-fold dilution; 
30 pi) were simultaneously injected into separate carrier 
streams using an automated rotary PTFE valve. Further 
downstream, the antiserum and serum zones were synchron­
ously merged at a T-connector and passed through a mixing
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Fig. 1. Merging zones manifold for the immunoprecipitin reaction between human IgG (30 pi) and goat anti-human IgG antiserum (30 pi) 
introduced into separate PEG - NaCI carrier streams. The dispersion of the human IgG in the manifold was 11
coil (20 cm) into a flow-through cell (volume 7.9 pi, path 
length 10 mm) housed in a spectrophotom eter (Varian 
VUV-50). To ensure complete mixing of the merged zones a 
close-packed glass bead column (4 cm x 1.5 mm i.d.; bead size 
80 mesh) was incorporated into the mixing coil. The turbidity 
was constantly monitored (340 nm) and the output fed to a 
recorder and an A/D converter (HP 3438A; 3.5 digit).
The rate of reaction was determined by stopping a segment 
of the merged serum and antiserum zones in the flow cell and 
performing a two-point kinetic analysis. This was achieved by 
switching off the peristaltic pump 14 s after sample injection, 
measuring the turbidity 30 and 60 s later and then reactivating 
the pump to flush out the reaction mixture. Complete 
automation of the FIA  manifold and data collection and 
treatm ent were as previously described.9-10
Results and Discussion 
Static Experiments
A wavelength scan (280-520 nm) for the antiserum, a human 
serum standard and the resultant immunoprecipitin complex 
‘showed that turbidimetric detection at 340 nm gave the 
optimum signal to background ratio for the complex. A 
human serum IgG standard (1778 mg dl-1) was then analysed 
at varying dilutions and the resultant data are given in Table 1. 
It shows that serum dilutions of 800-fold and more gave rise to 
the condition of antibody (antiserum) excess and that a serum 
dilution of only 500-fold gave rise to the condition of antigen 
(serum) excess. As the concentration of the standard used was 
above the upper limit of the normal clinical range, a dilution of 
800-fold was chosen for serum standards and samples in order 
to provide maximum sensitivity commensurate with the 
condition of antibody excess being met for the majority of 
samples. Equal volumes of serum and antiserum were used in 
the above experiments to facilitate the transfer of the reaction 
to a merging zones FIA  manifold.
A series of human serum IgG standards covering the range 
0-1778 mg dl-1 was then analysed by the above procedure 
after 800-fold manual dilution. The correlation coefficient (r) 
for the resultant calibration graph was 0.997, indicating that 
the top standard was within the antibody excess region and 
that the reaction conditions were suitable for a practical 
analytical method based on FIA.
Stop-flow Merging Zones FIA
Experiments were initially carried out in the antibody excess 
region only (0-1778 mg d l-1 of IgG), using dilutions of 80-fold 
for the antiserum and 800-fold for the standards and samples. 
The results obtained for five replicate injections of each 
standard are shown in Table 2 and indicate an acceptable 
precision at the higher end of the range. Owing to the long 
induction period necessary for the development of the 
immunoprecipitin reaction, however, the sensitivity and 
reproducibility are poor at lower serum IgG concentrations
Table 1. Increase in turbidity versus human serum standard (1778 
mg dl-1) dilution. All experiments performed in duplicate
Turbidity,
Serum dilution absorbance units
1000 ................................ 0.127
900........................................ 0.133
800  0.162
700 . .  . .  . .  . .  0.166
600........................................ 0.165
500........................................ 0.132
Table 2. Human serum IgG concentration versus increase in turbidity 
using a merging zones FIA manifold. All results are means of five 
experiments
Standard Relatve
Slope/ deviation/ standard
Serum IgG/ absorbance absorbance deviation,
mg dl-1 units min-1 units min-1 %
0 0 0 —
266 0 0 —
533 0.0053 0.0008 15.1
889 0.0147 0.0003 2.0
1155 0.0176 0.0012 6.8
1422 0.0233 0.0013 5.6
1778 0.0275 0.0013 2.5
under the conditions used. This could be improved by 
increasing the stop time in the flow cell or by reducing serum 
and antiserum dilution, but this would lead to longer analysis 
times or higher reagent costs. U nder the conditions described, 
the sampling rate was 40 samples per hour and the reagent cost 
was less than lp  per analysis (i.e ., less than 1 pi of undiluted 
antiserum per assay).
The between-batch reproducibility of the technique is 
shown in Fig. 2. The error bars indicate the range for the 
pooled data, which consisted of five results for each standard 
on the first run and five results for each standard on the second 
run 1 week later. Each point represents the mean of the ten 
pooled results. The shape of the calibration graph is charac­
teristic of immunoprecipitin reactions, with very slow reaction 
rates at low concentrations, rising through a linear region to a 
plateau at the equivalence point. This shape was shown to be 
reproducible over several weeks and therefore a single-point 
calibration can be used when required, as with commercial 
rate nephelometers.6 The excess of antigen can be determined 
by dilution of suspect samples or by the use of single channel 
stop-flow F IA .10
Quantitation of Serum Samples
For the analysis of nine human serum samples and the US 
National Reference Preparation, IgG standards covering the 
range 0-3556 mg dl-1 were used, with the antibody excess 
region covered by six standards up to 2844 mg dl-1 . A
ANALYST, N O V EM BER 1985, VOL. 110
Table 3. Flow injection (FIA) and radial immunodiffusion (RID) 
results for ten human serum samples. FIA results are the means of two 
replicates.
Sample
No.
Slope/ 
absorbance 
units min-1
IgG concentration/mg^l- 1 
FIA RID
■ Difference/ 
m gdl-1
1 0.0141 877 930 -5 3
2 0.0322 2693 2800 -1 0 7
3 0.0096 643 650 - 7
4 0.0300 2402 2250 + 152
5 0.0106 689 500 + 189
6 0.0155 967 890 +77
7 0.0195 1267 1230 +37
8 0.0064 532 670 -1 3 8
9 0.0170 1069 1170 -101
10* 0.0180 1145 1128 + 17
* US National Reference Preparation.
second-order curve fit of the data, as described by R itchie,11 
was used in preference to a linear least-squares fit. The results 
obtained from the FIA technique are compared with the 
results obtained from RID  in Table 3, and the correlation 
between them can be described by the equation (FIA) = 
0.98(RID) + 29, with a correlation coefficient (r) of 0.988, 
indicating the acceptability of the FIA  method in comparison 
with the routinely used RID  technique.
The result given for the US National Reference Preparation 
(1145 mg dl-1) compares well with the quoted result (1128 
mg d l-1) and seven determinations over a period of several 
weeks, using fresh standards each tim e, gave a between-batch 
relative standard deviation of 9.8%. This could be due in part 
to the long-term instability of the reconstituted serum and the 
within-batch precision for sets of ten results ranged from 3.6 to 
5.2%. The quoted result represents the mean of 232 analyses, 
carried out by 27 different collaborators, on batches of a 
pooled human serum sample, using a variety of different 
analytical m ethods.12
Conclusions
The results show that the stop-flow merging zones FIA  
technique is suitable for the determination of human serum 
IgG using rate turbidimetric detection. The method provides a 
rapid quantitative result 90 s after sample injection and no 
sample pre-treatm ent, other than dilution, is needed. The cost 
per assay is governed by the amount of antiserum used, and 
even allowing for wastage during the injection procedure, less 
than 1 pi of undiluted antiserum is consumed for each analysis.
By changing the serum and antiserum dilutions the tech­
nique could be extended to the analysis of several other 
plasma proteins and certain therapeutic drugs.
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Fig. 2. Calibration graph for a range of human IgG standards 
showing between-batch reproducibility for two sets of experiments. 
The error bars indicate the range of the pooled data for each standard
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